<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence - Mattick, RP - 2014 | Cochrane Library</title> <meta content="Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence - Mattick, RP - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence - Mattick, RP - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002207.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence" name="citation_title"/> <meta content="Richard P Mattick" name="citation_author"/> <meta content="University of New South Wales" name="citation_author_institution"/> <meta content="R.Mattick@unsw.edu.au" name="citation_author_email"/> <meta content="Courtney Breen" name="citation_author"/> <meta content="University of New South Wales" name="citation_author_institution"/> <meta content="Jo Kimber" name="citation_author"/> <meta content="University of New South Wales" name="citation_author_institution"/> <meta content="Marina Davoli" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD002207.pub4" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/02/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002207.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Buprenorphine [*therapeutic use]; Maintenance Chemotherapy [methods]; Methadone [*therapeutic use]; Narcotic Antagonists [*therapeutic use]; Narcotics [therapeutic use]; Opioid‐Related Disorders [*rehabilitation]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002207.pub4&amp;doi=10.1002/14651858.CD002207.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002207\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002207\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002207.pub4",title:"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence",firstPublishedDate:"Feb 6, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Drugs and Alcohol Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002207.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002207.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002207.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002207.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002207.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002207.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002207.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002207.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002207.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002207.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>26739 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002207.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-sec-0102"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/appendices#CD002207-sec-0107"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/table_n/CD002207StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/table_n/CD002207StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information#CD002207-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Richard P Mattick</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information#CD002207-cr-0003">Courtney Breen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information#CD002207-cr-0004">Jo Kimber</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information#CD002207-cr-0005">Marina Davoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information/en#CD002207-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 February 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002207.pub4">https://doi.org/10.1002/14651858.CD002207.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002207-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002207-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002207-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002207-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002207-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002207-abs-0001" lang="en"> <section id="CD002207-sec-0001"> <h3 class="title" id="CD002207-sec-0001">Background</h3> <p>Buprenorphine maintenance treatment has been evaluated in randomised controlled trials against placebo medication, and separately as an alternative to methadone for management of opioid dependence. </p> </section> <section id="CD002207-sec-0002"> <h3 class="title" id="CD002207-sec-0002">Objectives</h3> <p>To evaluate buprenorphine maintenance compared to placebo and to methadone maintenance in the management of opioid dependence, including its ability to retain people in treatment, suppress illicit drug use, reduce criminal activity, and mortality. </p> </section> <section id="CD002207-sec-0003"> <h3 class="title" id="CD002207-sec-0003">Search methods</h3> <p>We searched the following databases to January 2013: Cochrane Drugs and Alcohol Review Group Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Current Contents, PsycLIT, CORK, Alcohol and Drug Council of Australia, Australian Drug Foundation, Centre for Education and Information on Drugs and Alcohol, Library of Congress, reference lists of identified studies and reviews. We sought published/unpublished randomised controlled trials (RCTs) from authors. </p> </section> <section id="CD002207-sec-0004"> <h3 class="title" id="CD002207-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of buprenorphine maintenance treatment versus placebo or methadone in management of opioid‐dependent persons. </p> </section> <section id="CD002207-sec-0005"> <h3 class="title" id="CD002207-sec-0005">Data collection and analysis</h3> <p>We used Cochrane Collaboration methodology.</p> </section> <section id="CD002207-sec-0006"> <h3 class="title" id="CD002207-sec-0006">Main results</h3> <p>We include 31 trials (5430 participants), the quality of evidence varied from high to moderate quality. </p> <p>There is high quality of evidence that buprenorphine was superior to placebo medication in retention of participants in treatment at all doses examined. Specifically, buprenorphine retained participants better than placebo: at low doses (2 ‐ 6 mg), 5 studies, 1131 participants, risk ratio (RR) 1.50; 95% confidence interval (CI) 1.19 to 1.88; at medium doses (7 ‐ 15 mg), 4 studies, 887 participants, RR 1.74; 95% CI 1.06 to 2.87; and at high doses (≥ 16 mg), 5 studies, 1001 participants, RR 1.82; 95% CI 1.15 to 2.90. However, there is moderate quality of evidence that only high‐dose buprenorphine (≥ 16 mg) was more effective than placebo in suppressing illicit opioid use measured by urinanalysis in the trials, 3 studies, 729 participants, standardised mean difference (SMD) ‐1.17; 95% CI ‐1.85 to ‐0.49, Notably, low‐dose, (2 studies, 487 participants, SMD 0.10; 95% CI ‐0.80 to 1.01), and medium‐dose, (2 studies, 463 participants, SMD ‐0.08; 95% CI ‐0.78 to 0.62) buprenorphine did not suppress illicit opioid use measured by urinanalysis better than placebo. </p> <p>There is high quality of evidence that buprenorphine in flexible doses adjusted to participant need,was less effective than methadone in retaining participants, 5 studies, 788 participants, RR 0.83; 95% CI 0.72 to 0.95. For those retained in treatment, no difference was observed in suppression of opioid use as measured by urinalysis, 8 studies, 1027 participants, SMD ‐0.11; 95% CI ‐0.23 to 0.02 or self report, 4 studies, 501 participants, SMD ‐0.11; 95% CI ‐0.28 to 0.07, with moderate quality of evidence. </p> <p>Consistent with the results in the flexible‐dose studies, in low fixed‐dose studies, methadone (≤ 40 mg) was more likely to retain participants than low‐dose buprenorphine (2 ‐ 6 mg), (3 studies, 253 participants, RR 0.67; 95% CI: 0.52 to 0.87). However, we found contrary results at medium dose and high dose: there was no difference between medium‐dose buprenorphine (7 ‐ 15 mg) and medium‐dose methadone (40 ‐ 85 mg) in retention, (7 studies, 780 participants, RR 0.87; 95% CI 0.69 to 1.10) or in suppression of illicit opioid use as measured by urines, (4 studies, 476 participants, SMD 0.25; 95% CI ‐0.08 to 0.58) or self report of illicit opioid use, (2 studies, 174 participants, SMD ‐0.82; 95% CI ‐1.83 to 0.19). Similarly, there was no difference between high‐dose buprenorphine (≥ 16 mg) and high‐dose methadone (≥ 85 mg) in retention (RR 0.79; 95% CI 0.20 to 3.16) or suppression of self‐reported heroin use (SMD ‐0.73; 95% CI ‐1.08 to ‐0.37) (1 study, 134 participants). </p> <p>Few studies reported adverse events ; two studies compared adverse events statistically, finding no difference between methadone and buprenorphine, except for a single result indicating more sedation among those using methadone. </p> </section> <section id="CD002207-sec-0007"> <h3 class="title" id="CD002207-sec-0007">Authors' conclusions</h3> <p>Buprenorphine is an effective medication in the maintenance treatment of heroin dependence, retaining people in treatment at any dose above 2 mg, and suppressing illicit opioid use (at doses 16 mg or greater) based on placebo‐controlled trials. </p> <p>However, compared to methadone, buprenorphine retains fewer people when doses are flexibly delivered and at low fixed doses. If fixed medium or high doses are used, buprenorphine and methadone appear no different in effectiveness (retention in treatment and suppression of illicit opioid use); however, fixed doses are rarely used in clinical practice so the flexible dose results are more relevant to patient care. Methadone is superior to buprenorphine in retaining people in treatment, and methadone equally suppresses illicit opioid use. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002207-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002207-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002207-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002207-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002207-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002207-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002207-abs-0004" lang="en"> <h3>Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</h3> <p><b>Background</b> </p> <p>Methadone is widely used as a replacement for illicit opioid use such as heroin in medically‐supported opioid substitution maintenance programmes. Two other drugs have been used to help reduce illicit opioid use, specifically buprenorphine and LAAM (levo‐alpha‐acetylmethadol). LAAM is not used in current clinical practice. Buprenorphine is currently used and can reduce illicit opioid use compared with placebo, although it is less effective than methadone. Buprenorphine is an opioid drug that is not as potent as heroin and methadone, although the effects of buprenorphine may last longer. Buprenorphine can be taken once every two days. The trials include different formulations of buprenorphine: sublingual solution, sublingual tablets, combined buprenorphine/naloxone sublingual tablet and an implant. </p> <p><b>Key results</b> </p> <p>The review of trials found that buprenorphine at high doses (16 mg) can reduce illicit opioid use effectively compared with placebo, and buprenorphine at any dose studied retains people in treatment better than placebo. </p> <p>Buprenorphine appears to be less effective than methadone in retaining people in treatment, if prescribed in a flexible dose regimen or at a fixed and low dose (2 ‐ 6 mg per day). Buprenorphine prescribed at fixed doses (above 7 mg per day) was not different from methadone prescribed at fixed doses (40 mg or more per day) in retaining people in treatment or in suppression of illicit opioid use. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002207-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002207-sec-0102"></div> <h3 class="title" id="CD002207-sec-0103">Implications for practice</h3> <section id="CD002207-sec-0103"> <p>The implications of this review are clear for clinical practice. Despite the results showing that buprenorphine (especially at high doses) is an effective maintenance therapy for heroin dependence when compared with placebo, methadone maintenance treatment at flexible doses is better able to retain people in treatment. Both treatments suppress heroin use. Buprenorphine should be supported as a medication to use in substitution maintenance treatment, where higher doses of methadone cannot be administered or methadone is not tolerated, or simply to provide patient and clinician choice. Given buprenorphine's different pharmacological properties, it may have advantages in some settings and under some policies where its relative safety and alternate‐day administration are useful clinically compared to methadone. </p> </section> <h3 class="title" id="CD002207-sec-0104">Implications for research</h3> <section id="CD002207-sec-0104"> <p>There does not appear to be any need for further randomised control trials of the relative efficacy of methadone compared with buprenorphine. There does appear to be a need to undertake studies which will clarify factors responsible for retention in the first few weeks or months of treatment in buprenorphine versus methadone. One way of addressing this issue would be to compare a standard induction as used in some of the trials reported herein with a rapid induction onto buprenorphine, with the potential to have a further comparison of induction onto methadone. Problems in the methods of induction onto buprenorphine within the trials analysed might partly explain the inferiority of buprenorphine shown in this review. It would be ideal if such a trial were to be conducted under double‐blind conditions, particularly in terms of the rapid versus standard induction onto buprenorphine. Other outcome measures could be included in future studies, such as self‐reported drug use, criminal activity, physical health, and psychological health, which were too infrequently and irregularly reported in the literature analysed in the current review. </p> <p>There is enough research evidence to show that buprenorphine in low, medium or high doses is more effective than placebo in retaining people in treatment, and in reducing heroin use at high doses. Future trials involving placebo (or indeed short‐term maintenance where people are terminated from treatment after a few weeks of intervention) should consider the ethical implications of providing substandard (i.e., placebo or short‐term treatment), given the strength of the available evidence. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002207-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002207-sec-0022"></div> <div class="table" id="CD002207-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: comparison between flexible‐dose methadone and buprenorphine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Buprenorphine maintenance compared with methadone maintenance for opioid dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> People with opioid dependence. </p> <p><b>Settings:</b> Inpatient and outpatient </p> <p><b>Intervention:</b> Buprenorphine maintenance at flexible doses </p> <p><b>Comparison:</b> Methadone maintenance at flexible doses </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Retention in treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.83</p> <p>(0.73 to 0.95)*</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 (1391);</p> <p>5 double‐blind (788)</p> <p>6 open‐label (603)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater retention in the methadone group.</p> <p>* the heterogeneity is significant.</p> <p>When the double‐blind studies are analysed separately the heterogeneity is not significant and the RR is 0.83 (0.72 to 0.95) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morphine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.11</p> <p>(‐0.23 to 0.02)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 (1027)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported heroin use</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.11</p> <p>(‐0.28 to 0.07)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 (501)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cocaine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.10</p> <p>(‐0.05 to 0.25)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 (919)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.05</p> <p>(‐0.09 to 0.18]</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 (859)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; SMD: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD002207-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for the comparison between high‐dose buprenorphine and placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Buprenorphine maintenance compared with methadone maintenance for opioid dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> People with opioid dependence. </p> <p><b>Settings:</b> Inpatient and outpatient </p> <p><b>Intervention:</b> Buprenorphine maintenance at high doses (16 mg) </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Retention in treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.82</p> <p>(1.15 to 2.90)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1001 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater retention in buprenorphine group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morphine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.17</p> <p>(‐1.85 to ‐0.49)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>729 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fewer morphine‐positive urines in buprenorphine group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.65</p> <p>(‐4.94 to 1.65)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>336 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; SMD: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002207-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002207-sec-0023"></div> <section id="CD002207-sec-0024"> <h3 class="title" id="CD002207-sec-0024">Description of the condition</h3> <p>Opioids are a class of compounds that elicit analgesic effect by binding to opioid receptors within the central and peripheral nervous system. Opioids include natural opiates such as opium (from the poppy) and morphine, and natural derivatives or synthetic compounds such as heroin (diacetylmorphine), oxycodone, buprenorphine and methadone. </p> <p>Opioids produce euphoria and have been associated with recreational use. They are generally consumed by injection or inhalation of the fumes produced by heating. Regular use of opioids can lead to opioid dependence. Opioid dependence is a medical diagnosis that involves the inability to cease using opioids. The DSM‐IV criteria for dependence (cited here as the studies predominantly use DSM‐IV, whereas DSM‐V was released in 2013) require three or more of the following features: </p> <p> <ol id="CD002207-list-0001"> <li> <p>A strong desire or sense of compulsion to take the drug;</p> </li> <li> <p>Difficulties in controlling drug‐taking behaviour in terms of its onset, termination, or levels of use; </p> </li> <li> <p>A physiological withdrawal state when drug use is stopped or reduced, as evidenced by: the characteristic withdrawal syndrome for the substance; or use of the same (or a closely related) substance with the intention of relieving or avoiding withdrawal symptoms; </p> </li> <li> <p>Evidence of tolerance, such that increased doses of the drug are required in order to achieve effects originally produced by lower doses; </p> </li> <li> <p>Progressive neglect of alternative pleasures or interests because of drug use, increased amount of time necessary to obtain or take the drug or to recover from its effects; </p> </li> <li> <p>Persisting with drug use despite clear evidence of overtly harmful consequences, such as harm to the liver, depressive mood states or impairment of cognitive functioning. </p> </li> </ol> </p> <p>The illegality of opioids such as heroin precludes the accurate assessment of how many people use these drugs, but recent estimates suggest there are between 15 and 39 million problem opioid users worldwide (<a href="./references#CD002207-bbs2-0076" title="DegenhardtL , HallW . Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet2012;379(9810):55‐70. ">Degenhardt 2012</a>), and although the prevalence of opioid dependence is low (0.6 ‐ 0.8% of the global population; <a href="./references#CD002207-bbs2-0095" title="UNODC . World Drug Report 2012. www.unodc.org/unodc/en/data‐and‐analysis/WDR‐2012.html (accessed 6 January 2014)2012; Vol. Sales No E.12.XI.1. ">UNODC 2012</a>), the burden to the individual and the community is significant. Illicit opioid dependence is a significant public health problem with heroin use associated with the spread of infectious disease (e.g., HIV, hepatitis B and C) and overdose deaths (<a href="./references#CD002207-bbs2-0075" title="DegenhardtL , BucelloC , MathersB , BrieglebC , AliH , HickmanM , et al. Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta‐analysis of cohort studies. Addiction2011;106(1):32‐51. ">Degenhardt 2011</a>; <a href="./references#CD002207-bbs2-0087" title="MathersBM , DegenhardtL , PhillipsB , WiessingL , HickmanM , StrathdeeSA , et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet2008;372(9651):1733‐45. ">Mathers 2008</a>; <a href="./references#CD002207-bbs2-0092" title="NelsonPK , MathersBM , CowieB , HaganH , DesJarlaisD , HoryniakD , et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet2011;378(9791):571‐83. ">Nelson 2011</a>). </p> </section> <section id="CD002207-sec-0025"> <h3 class="title" id="CD002207-sec-0025">Description of the intervention</h3> <p>Dole and Nyswander defined opioid dependence as a "physiological disease characterised by a permanent metabolic deficiency" which was best managed by administering the opioid‐dependent person "a sufficient amount of drug to stabilise the metabolic deficiency" (<a href="./references#CD002207-bbs2-0077" title="DoleVP , NyswanderM . A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA1965;193:646‐50. ">Dole 1965</a>). In the early 1960s they introduced orally‐administered maintenance doses of the synthetic opioid drug methadone as a treatment for opioid dependence. Maintenance treatment is designed to be an ongoing treatment. The substitution of legal opioids in known doses and purity provides an opportunity to stabilise the person by eliminating withdrawal, craving, participation in obtaining illegal opioids and use of needles. </p> <p>Methadone maintenance treatment (MMT) has been one of the main forms of treatment for opioid dependence. As described elsewhere (<a href="./references#CD002207-bbs2-0079" title="FaggianoF , Vigna‐TagliantiF , VersinoE , LemmaP . Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002208] ">Faggiano 2003</a>; <a href="./references#CD002207-bbs2-0088" title="MattickRP , OliphantD , WardJ , HallW . The effectiveness of other opioid replacement therapies: LAAM, heroin, buprenorphine, naltrexone and injectable maintenance. Methadone maintenance and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers, 1998:123‐60. [DOI: 10.1002/14651858] ">Mattick 1998</a>; <a href="./references#CD002207-bbs2-0089" title="MattickRP , BreenC , KimberJ , DavoliM . Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD002209.pub2] ">Mattick 2009</a>), maintenance treatment with oral methadone appears to be an effective and accepted intervention for illicit opioid (heroin) dependence, and it is widely used in some countries. Yet MMT has a number of negative characteristics which potentially influence its effectiveness and which have led to an interest in alternative pharmacotherapies and methods of treatment delivery (<a href="./references#CD002207-bbs2-0088" title="MattickRP , OliphantD , WardJ , HallW . The effectiveness of other opioid replacement therapies: LAAM, heroin, buprenorphine, naltrexone and injectable maintenance. Methadone maintenance and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers, 1998:123‐60. [DOI: 10.1002/14651858] ">Mattick 1998</a>). The negative aspects of methadone are set out below. </p> <p>One negative aspect of methadone is its potential to produce and/or maintain dependence on opioids, such that people experience withdrawal if a daily dose is missed, and detoxification can be a lengthy and difficult process which can discourage people from attempting withdrawal (of course, withdrawal from heroin and other opioids have similar problems). Additionally, because methadone is a full opioid agonist, there is no ceiling to the level of respiratory depression or sedation which methadone can induce, and methadone overdose can therefore be fatal (<a href="./references#CD002207-bbs2-0078" title="DrummerOH , OpeskinK , SyrjanenM , CordnerSM . Methadone toxicity causing death in ten subjects starting on a methadone maintenance program.. American Journal of Forensic Medicine and Pathology1992;13(4):346–50. ">Drummer 1992</a>). Although it is a long‐acting opioid, in some countries and settings, the inconvenience of daily dosing and clinic visits may be unattractive to clients, and restrictions imposed by the daily dosing schedule on clients' general lifestyle and on opportunities to sustain employment may also limit its acceptance to heroin users. The provision of takeaway doses of methadone results in problems of diversion of the drug for illicit use by those not in treatment, although the extent of this problem varies across countries. Finally, heroin users have developed their own 'lore' regarding methadone's negative effects, although their views may not always be accurate or favourable. Thus, despite its many advantages, methadone maintenance appears to have limited suitability for some people. In some countries there may be restrictions on the use of methadone as far as doses and duration are concerned, and this may impair adequate clinical practice. These factors may restrict the ability of methadone to attract certain users into treatment, and the examination of alternative medications to broaden the range of pharmacotherapies has been the focus of research over recent years (e.g., <a href="./references#CD002207-bbs2-0086" title="LingW , WessonDR . Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug and Alcohol Dependence2003;70(2 Suppl):S49‐57. ">Ling 2003</a>; <a href="./references#CD002207-bbs2-0091" title="MitchellTB , WhiteJM , SomogyiAA , BochnerF . Slow‐release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction2004;99(8):940‐5. ">Mitchell 2004</a>). </p> </section> <section id="CD002207-sec-0026"> <h3 class="title" id="CD002207-sec-0026">How the intervention might work</h3> <p>There are a number of alternatives to methadone as a maintenance agent in the management of opioid dependence, as all opioids show cross‐tolerance. The most promising of these involve pharmacotherapies which treat people with a pharmaceutical‐grade opioid which has a long duration of action. These include the opiate partial agonist buprenorphine, the full agonist levo‐alpha‐acetylmethadol (LAAM) (<a href="./references#CD002207-bbs2-0071" title="ClarkNC , LintzerisN , GijsbersA , WhelanG , DunlopA , RitterA , LingWW . LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD002210] ">Clark 2002</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>) and sustained released morphine sulphate (<a href="./references#CD002207-bbs2-0091" title="MitchellTB , WhiteJM , SomogyiAA , BochnerF . Slow‐release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction2004;99(8):940‐5. ">Mitchell 2004</a>; <a href="./references#CD002207-bbs2-0097" title="WhiteJM , LopatkoOV . Opioid maintenance: a comparative review of pharmacological strategies. Expert Opinion on Pharmacotherapy2007;8(1):1‐11. ">White 2007</a>). LAAM is no longer used in clinical practice. In addition, heroin‐assisted treatment has been used in the management of opioid dependence, most notably in Switzerland (<a href="./references#CD002207-bbs2-0093" title="PernegerTV , GinerF , DelRioM , MinoA . Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ1998;317(7150):13‐8. ">Perneger 1998</a>). </p> <p>This review focuses on the role of buprenorphine as a maintenance therapy in the management of opioid dependence. Buprenorphine is a potent synthetic opioid analgesic initially used for the management of acute pain. Pharmacologically, buprenorphine causes morphine‐like subjective effects and produces cross‐tolerance to other opioids. </p> <p>Unlike methadone and heroin (which are full agonists), buprenorphine is a partial agonist and exerts weaker opioid effects at opioid receptor sites. This partial agonist action appears to make buprenorphine safer in overdose. Other benefits of buprenorphine may include an easier withdrawal phase and, because of the longer duration of action, the option of alternate‐day dosing. </p> <p>It was during the initial development of buprenorphine as an analgesic in the 1970s that its potential utility as a substitution agent in the treatment of opioid dependence was recognised. Early work (<a href="./references#CD002207-bbs2-0084" title="JasinskiD , PevnickJ , GriffithJ . Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry1978;35(4):501‐6. ">Jasinski 1978</a>) using buprenorphine administered by the subcutaneous route, characterised it as an opioid with low physical dependence liability with a minimal withdrawal syndrome. Subsequently, others (<a href="./references#CD002207-bbs2-0080" title="FudalaPJ , JaffeJH , DaxEM , JohnsonRE . Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate‐day administration and abrupt withdrawal. Clinical Pharmacology and Therapeutics1990;47(4):525‐34. ">Fudala 1990</a>) provided evidence that buprenorphine does produce a mild to moderate mu‐agonist withdrawal syndrome. It was thought that at doses somewhat greater than those used for analgesia it could be used in the treatment of opioid dependence (<a href="./references#CD002207-bbs2-0084" title="JasinskiD , PevnickJ , GriffithJ . Human pharmacology and abuse potential of the analgesic buprenorphine. Archives of General Psychiatry1978;35(4):501‐6. ">Jasinski 1978</a>). Since that time a substantial international research effort has addressed the efficacy of buprenorphine maintenance therapy in randomised controlled trials (RCTs). </p> </section> <section id="CD002207-sec-0027"> <h3 class="title" id="CD002207-sec-0027">Why it is important to do this review</h3> <p>Clinical trials conducted in the USA. showed buprenorphine to be superior to placebo medication, but when buprenorphine and methadone maintenance were compared in a series of impressive studies using fixed doses of the drugs, the results were mixed. Some of the fixed‐dose studies showed no difference in efficacy, whereas others showed superiority for methadone, and yet others showed the reverse pattern. The investigators in these fixed‐dose studies frequently concluded that the doses of buprenorphine or methadone chosen were too low, or that poor induction regimens led to poor retention and affected trial results. A series of variable‐ (or flexible‐) dose studies have been conducted and shown essentially equivalent results for the two drugs. In these flexible‐dose studies, dose is adjusted to individual need rather than participants being randomly assigned to a set and unchanging dose, as in the fixed‐dose studies. </p> <p>Given the mixed results of the early studies, it is important to attempt a systematic integration of the literature. Of particular importance is separately assessing the fixed‐ and flexible‐dose studies and considering the results in the light of the differing doses and other individual trial features. Additionally, this review separately summarises the available placebo‐controlled trial results. </p> <p>This is an update of a Cochrane review, incorporating additional studies, which was first published in 2002 and updated in 2008. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002207-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002207-sec-0028"></div> <p>To evaluate buprenorphine maintenance compared to placebo and to methadone maintenance in the management of opioid dependence, including its ability to retain people in treatment, suppress illicit drug use, reduce criminal activity, and mortality. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002207-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002207-sec-0029"></div> <section id="CD002207-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002207-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials of buprenorphine maintenance versus methadone maintenance or versus placebo medication in the management of opioid dependence. </p> </section> <section id="CD002207-sec-0032"> <h4 class="title">Types of participants</h4> <p>Individuals dependent on heroin or other opioids. We made no distinction between those using heroin and those in methadone treatment prior to entering the research trial treatment. We excluded trials of pregnant women, as a separate review of opioid maintenance therapy for pregnant women has been completed (<a href="./references#CD002207-bbs2-0090" title="MinozziS , AmatoL , BellisarioC , FerriM , DavoliM . Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD006318.pub3] ">Minozzi 2013</a>). </p> </section> <section id="CD002207-sec-0033"> <h4 class="title">Types of interventions</h4> <p><b><i>Experimental interventions:</i> </b> Buprenorphine maintenance therapy (BMT) using doses above 1 mg ("which was adopted to serve essentially as a placebo" dose in the context of heroin/opioid dependence (<a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>, p.477)), using sublingual tablets, an ethanol‐based solution and more recently implants, containing buprenorphine. </p> <p><b><i>Control Interventions:</i> </b> Methadone maintenance therapy (MMT) with doses of 20 mg methadone per day or higher, or placebo, or 1 mg of buprenorphine per day (as adopted by Ling to "serve essentially as a placebo" dose in one study (<a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>, p.477)). </p> <p>We excluded studies using methadone or buprenorphine for detoxification without a maintenance phase. </p> </section> <section id="CD002207-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p><b><i>Primary outcomes</i> </b> </p> <p> <ol id="CD002207-list-0002"> <li> <p>Retention in treatment as measured by intention‐to‐treat (i.e., the number of participants still in treatment at the end of the study); </p> </li> <li> <p>Use of opioids as measured by: a) urinalysis results positive for heroin metabolite (i.e., morphine); b) self‐reported heroin use; </p> </li> <li> <p>Use of other substances of abuse as measured by: a) urinalysis results positive for cocaine; b) urinalysis results positive for benzodiazepines; </p> </li> <li> <p>Criminal activity as measured by self report;</p> </li> <li> <p>Mortality.</p> </li> </ol> </p> <p><b><i>Secondary outcomes</i> </b> </p> <p> <ol id="CD002207-list-0003"> <li> <p>Physical health;</p> </li> <li> <p>Psychological health;</p> </li> <li> <p>Adverse effects of medication.</p> </li> </ol> </p> </section> </section> <section id="CD002207-sec-0035"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002207-sec-0036"> <h4 class="title">Electronic searches</h4> <p>In consultation with a drug and alcohol research information specialist, we developed a specific search strategy for each database searched with no language restrictions. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), The Cochrane Library, 2013, Issue 1, PubMed (January 2003 to January 2013), and EMBASE (January 2003 to January 2013); <i>see</i><a href="./appendices#CD002207-sec-0108">Appendix 1</a>; <a href="./appendices#CD002207-sec-0109">Appendix 2</a>; and <a href="./appendices#CD002207-sec-0110">Appendix 3</a>. </p> <p>As several drug and alcohol journals are not indexed on the main electronic databases, we also searched the following databases: </p> <p> <ul id="CD002207-list-0004"> <li> <p>Current Contents;</p> </li> <li> <p>PsycLIT;</p> </li> <li> <p>CORK [www.projectcork.org/database_search/search_form.html];</p> </li> <li> <p>Alcohol and Drug Council of Australia (ADCA) [<a href="http://www.adca.org.au" target="_blank">www.adca.org.au</a>]; </p> </li> <li> <p>Australian Drug Foundation (ADF ‐VIC) [<a href="http://www.adf.org.au/" target="_blank">www.adf.org.au/</a>]; </p> </li> <li> <p>Centre for Education and Information on Drugs and Alcohol (CEIDA) [<a href="http://www.ceida.net.au/" target="_blank">www.ceida.net.au/</a>]; </p> </li> <li> <p>Australian Bibliographic Network (ABN).</p> </li> </ul> </p> </section> <section id="CD002207-sec-0037"> <h4 class="title">Searching other resources</h4> <p>We also searched the following:</p> <p> <ol id="CD002207-list-0005"> <li> <p>Some of the main electronic sources of ongoing trials (National Research Register, meta‐Register of Controlled Trials; Clinical Trials.gov; Agenzia Italiana del Farmaco); </p> </li> <li> <p>Conference proceedings likely to contain trials relevant to the review (US College on Problems of Drug Dependence ‐ CPDD); </p> </li> <li> <p>Library of Congress databases, for studies and book chapters with the key terms: buprenorphine, methadone, clinical trial, and randomised control trial; </p> </li> <li> <p>National focal points for drug research (e.g., National Institute of Drug Abuse (NIDA), National Drug &amp; Alcohol Research Centre (NDARC)); </p> </li> <li> <p>Reference lists of all relevant papers to identify further studies.</p> </li> </ol> </p> <p>We consulted authors of identified RCTs for any other published or unpublished RCTs comparing the efficacy of buprenorphine and methadone maintenance as therapies for opioid dependence. </p> </section> </section> <section id="CD002207-sec-0038"> <h3 class="title" id="CD002207-sec-0038">Data collection and analysis</h3> <section id="CD002207-sec-0039"> <h4 class="title">Selection of studies</h4> <p>We obtained each potentially relevant study located in the search, and two of four review authors independently assessed it for inclusion. Studies were eligible irrespective of publication status or language of publication. </p> </section> <section id="CD002207-sec-0040"> <h4 class="title">Data extraction and management</h4> <p>The two review authors who selected a study for inclusion then independently extracted the data for that study. Each review author assessed the same number of studies. We used a standardised checklist or data extraction, with a third review author acting as arbiter in cases of disagreement, and unresolved disagreements on inclusion, study quality or extraction being referred to the editor. Where required, we sought missing or clarifying information by contacting study authors. We handled multi‐arm studies (e.g., <a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>) by combining relevant groups and avoiding double‐counting of participants. Measurement scales were compatible across studies for the main outcomes, with dichotomous data or means and standard deviations being used in all cases. </p> </section> <section id="CD002207-sec-0041"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the new studies included in this updated version and reassessed the studies already included in the existing review, using the criteria and the method indicated in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD002207-bbs2-0083" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a><i>).</i> </p> <p>The recommended approach for assessing risk of bias in studies included in Cochrane reviews is a two‐part tool, addressing six specific domains (namely randomisation sequence generation, randomisation allocation concealment, blinding of participants and assessors, incomplete outcome data, selective reporting and other potential biases). The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgement, in terms of 'low', 'high' or 'unclear', relating to the risk of bias for that entry. To make these judgements we used the criteria indicated by Chapter 8 of the<i>Cochrane Handbook</i> and their applicability to the addiction field. </p> <p>For this updated review, we considered the following domains to be relevant: sequence generation, allocation concealment (avoidance of selection bias), blinding of participants, personnel and outcome assessor (performance and detection bias) and incomplete outcome data (attrition bias). See <a href="./appendices#CD002207-sec-0111">Appendix 4</a> for a detailed description of the criteria used. As sequence generation and allocation concealment were adequately described in only a minority of trials (leaving it unclear whether the process was or was not adequate), it was not possible to meaningfully analyse trials by stratifying on these randomisation variables. To address the better‐reported blinded/unblinded status, we report where possible the open‐label (unblinded) studies separately from the blinded comparisons. Where incomplete data were reported (especially in the case of urine analysis of ongoing drug use), we wrote to the authors of the study seeking those data and included them where available. </p> </section> <section id="CD002207-sec-0042"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated a standardised effect size for each study, based on the outcome measure reported. As the retention‐in‐treatment data are a dichotomous outcome, we calculated the risk ratio (RR) and its 95% confidence interval (CI). We estimated a standardised mean difference for continuous outcomes (urine results, self‐reported heroin use, and criminal activity). Urine data were provided in reports (or by authors in response to our request) in the form of the average number of positive urines and a standard deviation, by treatment group. </p> </section> <section id="CD002207-sec-0043"> <h4 class="title">Unit of analysis issues</h4> <p>The urine data are presented as a continuous outcome measure but are based on data requested directly from authors. This was necessary as urine results in the literature are routinely reported as the percentage of urine samples collected per treatment group that were positive or negative for a given drug (e.g., heroin) across the study period. These 'count data' are not compatible with the analysable data fields in Review Manager 5 (RevMan) (i.e., continuous, dichotomous, individual patient data). Based on advice provided by Cochrane statisticians, we asked the study authors to calculate the number of positive urines for each participant in each treatment group and derive a mean number of positive urines with a standard deviation, allowing for analysis of urine results as continuous data. These additional data were not available for four studies at the time of writing this review, and urine results are therefore not presented for these studies (<a href="./references#CD002207-bbs2-0013" title="KostenT , SchottenfeldR , ZiedonisD , FalcioniJ . Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease1993;181(6):358‐64. [MEDLINE: 1993274288] ">Kosten 1993</a>; <a href="./references#CD002207-bbs2-0022" title="NeriS , BrunoCM , PulvirentiD , MalaguarneraM , ItalianoC , MauceriB , et al. Randomised clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology2005;179(3):700‐4. ">Neri 2005</a>; <a href="./references#CD002207-bbs2-0023" title="OlivetoAH , FeingoldA , SchottenfeldR , JatlowP , KostenTR . Desipramine in opioid‐dependent cocaine abusers maintained on methadone or buprenorphine. Archives of General Psychiatry1999;56(9):812‐20. ">Oliveto 1999</a>; <a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000,</a>). </p> </section> <section id="CD002207-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistically significant heterogeneity among primary outcome studies with the Chi² test and I² heterogeneity test (<a href="./references#CD002207-bbs2-0082" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). A significant Chi² ( P &lt; 0.05) and I² of at least 50% was considered as statistical heterogeneity. </p> </section> <section id="CD002207-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We derived the pooled effect size estimate for each domain of measurement (retention in treatment, urine analysis results for heroin/morphine, urine analysis results for cocaine, and urine analysis results for benzodiazepines). Given the diverse treatment settings and countries of the studies involved, we used a random‐effects model. </p> <p>We integrated the results from the meta‐analytic review into a discussion, taking into consideration other publications such as studies of the pharmacology of methadone and buprenorphine. We took convergence of evidence from the meta‐analysis and from the narrative review to indicate a robust conclusion. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002207-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002207-sec-0046"></div> <section id="CD002207-sec-0047"> <h3 class="title">Description of studies</h3> <p>See the <a href="./references#CD002207-sec-0121" title="">Characteristics of included studies</a> table. </p> <p>Evidence on the efficacy of buprenorphine has come from placebo‐controlled trials (<a href="./references#CD002207-bbs2-0001" title="AhmadiJ . A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence2002;66(2):111‐4. ">Ahmadi 2002a</a>; <a href="./references#CD002207-bbs2-0003" title="AhmadiJ , AhmadiK , OhaeriJ . Controlled, randomised trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study. European Journal of Clinical Investigation2003;33(9):824‐9. ">Ahmadi 2003b</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004</a>; <a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>; <a href="./references#CD002207-bbs2-0011" title="KakkoJ , GrönbladhL , SvanborgKD , VonWachenfeldtJ , RückC , RawlingsB , et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry2007;164(5):797‐803. ">Kakko 2007</a>; <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>; <a href="./references#CD002207-bbs2-0018" title="LingW , CasadonteP , BeglowG , KampmanKM , PatkarA , BaileyGL , et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA2010;304(14):1576‐83. ">Ling 2010</a>; <a href="./references#CD002207-bbs2-0028" title="SchottenfeldRS , ChawarskiMC , MazlanM . Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double‐blind, placebo‐controlled trial. Lancet2008;371(9631):2192‐200. ">Schottenfeld 2008</a>), from fixed‐dosing studies of buprenorphine versus methadone maintenance treatment (<a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0003" title="AhmadiJ , AhmadiK , OhaeriJ . Controlled, randomised trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study. European Journal of Clinical Investigation2003;33(9):824‐9. ">Ahmadi 2003b</a>; <a href="./references#CD002207-bbs2-0032" title="BickelWK , StitzerML , BigelowGE , LiebsonIA , JasinskiDR , JohnsonRE . A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics1988;43(1):72‐8. [MEDLINE: 1988081296] ">Bickel 1988</a>; <a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0007" title="JohnsonR , JaffeJ , FudalaP . A controlled trial of buprenorphine treatment for opioid dependence. JAMA1992;267(20):2750‐5. [MEDLINE: 1992251936] ">Johnson 1992</a>; <a href="./references#CD002207-bbs2-0013" title="KostenT , SchottenfeldR , ZiedonisD , FalcioniJ . Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease1993;181(6):358‐64. [MEDLINE: 1993274288] ">Kosten 1993</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>; <a href="./references#CD002207-bbs2-0023" title="OlivetoAH , FeingoldA , SchottenfeldR , JatlowP , KostenTR . Desipramine in opioid‐dependent cocaine abusers maintained on methadone or buprenorphine. Archives of General Psychiatry1999;56(9):812‐20. ">Oliveto 1999</a>; <a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000</a>; <a href="./references#CD002207-bbs2-0027" title="SchottenfeldRS , ChawarskiMC , PakesJR , PantalonMV , CarrollKM , KostenTR . Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. American Journal of Psychiatry2005;162(2):340‐9. ">Schottenfeld 2005</a>; <a href="./references#CD002207-bbs2-0064" title="UehlingerC , DéglonJ , LivotiS , PetitjeanS , WaldvogelD , LadewigD . Comparison of buprenorphine and methadone in the treatment of opioid dependence. Eur Addict Res1998;4 Suppl 1:13‐8. ">Uehlinger 1998</a>) and from variable‐ or flexible‐dosing studies of buprenorphine versus methadone maintenance treatment (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0019" title="LintzerisN , RitterA , PanjariM , ClarkN , KutinJ , BammerG . Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation trial. American Journal on Addictions2004;13 Suppl 1:S29‐S41. ">Lintzeris 2004</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>; <a href="./references#CD002207-bbs2-0022" title="NeriS , BrunoCM , PulvirentiD , MalaguarneraM , ItalianoC , MauceriB , et al. Randomised clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology2005;179(3):700‐4. ">Neri 2005</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>; <a href="./references#CD002207-bbs2-0029" title="SoykaM , ZinggC , KollerG , KuefnerH . Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome:results form a randomised study. International Journal of Neuropsychopharmacology2008;11(5):641‐53. ">Soyka 2008a</a>; <a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>; <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b</a>). Many of the earlier studies used the sublingual solution formulation (<a href="./references#CD002207-bbs2-0007" title="JohnsonR , JaffeJ , FudalaP . A controlled trial of buprenorphine treatment for opioid dependence. JAMA1992;267(20):2750‐5. [MEDLINE: 1992251936] ">Johnson 1992</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>; <a href="./references#CD002207-bbs2-0023" title="OlivetoAH , FeingoldA , SchottenfeldR , JatlowP , KostenTR . Desipramine in opioid‐dependent cocaine abusers maintained on methadone or buprenorphine. Archives of General Psychiatry1999;56(9):812‐20. ">Oliveto 1999</a>; <a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>; <a href="./references#CD002207-bbs2-0027" title="SchottenfeldRS , ChawarskiMC , PakesJR , PantalonMV , CarrollKM , KostenTR . Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. American Journal of Psychiatry2005;162(2):340‐9. ">Schottenfeld 2005</a>; <a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>; <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b)</a> and a few more recent studies have used the combined buprenorphine‐naloxone tablet (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0011" title="KakkoJ , GrönbladhL , SvanborgKD , VonWachenfeldtJ , RückC , RawlingsB , et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry2007;164(5):797‐803. ">Kakko 2007</a>; <a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>). One study used buprenorphine implant formulation (<a href="./references#CD002207-bbs2-0018" title="LingW , CasadonteP , BeglowG , KampmanKM , PatkarA , BaileyGL , et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA2010;304(14):1576‐83. ">Ling 2010</a>). The remaining sixteen studies used the sublingual tablet formulation. </p> <section id="CD002207-sec-0048"> <h4 class="title">Results of the search</h4> <p>We identified 6495 studies through the electronic and other searches. Of these, we discarded 1794 studies as they were identified as duplicates. We eliminated a further 1733 studies after reviewing titles. We examined the full text of 61 studies, and eliminated a further 36, leaving 31 studies included in the analysis. See <a href="#CD002207-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD002207-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002207-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD002207-sec-0049"> <h4 class="title">Included studies</h4> <p>We include 31 studies (5430 participants) in this review.</p> <p><i><b>Country of origin of the included studies</b> </i> <br/> Fifteen studies were from North America (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0007" title="JohnsonR , JaffeJ , FudalaP . A controlled trial of buprenorphine treatment for opioid dependence. JAMA1992;267(20):2750‐5. [MEDLINE: 1992251936] ">Johnson 1992</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>; <a href="./references#CD002207-bbs2-0013" title="KostenT , SchottenfeldR , ZiedonisD , FalcioniJ . Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease1993;181(6):358‐64. [MEDLINE: 1993274288] ">Kosten 1993</a>; <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>; <a href="./references#CD002207-bbs2-0018" title="LingW , CasadonteP , BeglowG , KampmanKM , PatkarA , BaileyGL , et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA2010;304(14):1576‐83. ">Ling 2010</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>; <a href="./references#CD002207-bbs2-0023" title="OlivetoAH , FeingoldA , SchottenfeldR , JatlowP , KostenTR . Desipramine in opioid‐dependent cocaine abusers maintained on methadone or buprenorphine. Archives of General Psychiatry1999;56(9):812‐20. ">Oliveto 1999</a>; <a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>; <a href="./references#CD002207-bbs2-0027" title="SchottenfeldRS , ChawarskiMC , PakesJR , PantalonMV , CarrollKM , KostenTR . Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. American Journal of Psychiatry2005;162(2):340‐9. ">Schottenfeld 2005</a>; <a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>; <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b</a>), nine were from Europe (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>; <a href="./references#CD002207-bbs2-0011" title="KakkoJ , GrönbladhL , SvanborgKD , VonWachenfeldtJ , RückC , RawlingsB , et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry2007;164(5):797‐803. ">Kakko 2007</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0022" title="NeriS , BrunoCM , PulvirentiD , MalaguarneraM , ItalianoC , MauceriB , et al. Randomised clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology2005;179(3):700‐4. ">Neri 2005</a>; <a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>; <a href="./references#CD002207-bbs2-0029" title="SoykaM , ZinggC , KollerG , KuefnerH . Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome:results form a randomised study. International Journal of Neuropsychopharmacology2008;11(5):641‐53. ">Soyka 2008a</a>), four from the Middle East (<a href="./references#CD002207-bbs2-0001" title="AhmadiJ . A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence2002;66(2):111‐4. ">Ahmadi 2002a</a>; <a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0003" title="AhmadiJ , AhmadiK , OhaeriJ . Controlled, randomised trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study. European Journal of Clinical Investigation2003;33(9):824‐9. ">Ahmadi 2003b</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004</a>), two from Australia (<a href="./references#CD002207-bbs2-0019" title="LintzerisN , RitterA , PanjariM , ClarkN , KutinJ , BammerG . Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation trial. American Journal on Addictions2004;13 Suppl 1:S29‐S41. ">Lintzeris 2004;</a><a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>) and one from Asia (<a href="./references#CD002207-bbs2-0028" title="SchottenfeldRS , ChawarskiMC , MazlanM . Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double‐blind, placebo‐controlled trial. Lancet2008;371(9631):2192‐200. ">Schottenfeld 2008</a>). </p> <p><i><b>Characteristics of the participants</b> </i> <br/> The majority of participants in these studies were male, consistent with the profile of heroin‐dependant users generally. They tended to be approximately 30 years of age, with different previous treatment histories and prevalence of use of other drugs, again consistent with what is known about heroin users presenting for treatment. The number of participants in these studies varied between 40 in one study (<a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>) up to 736 in the study by <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>. The largest comparative trial of methadone versus buprenorphine included was reported by <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>, with 405 participants. Many of the studies had quite small numbers of participants in each individual treatment group. The characteristics of the participants and the inclusion and exclusion criteria were well described in all of the studies. </p> <p><i><b>Duration of intervention</b> </i> <br/> The interventions ranged in duration from 2 weeks through to 52 weeks. By and large, the interventions used clinically relevant doses of medication, although as noted earlier a number of the studies used predetermined fixed doses of medication (i.e., not tailored to individual treatment preference or need) and this created some limitations in terms of generalisability to day‐to‐day clinical practice, where flexible dosing is used. </p> <p><i><b>Characteristics of the intervention and types of comparisons</b> </i> </p> <p>Twenty studies involved comparisons of methadone and buprenorphine. The remaining eleven studies compared buprenorphine with placebo, where placebo was defined as either true placebo (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>; <a href="./references#CD002207-bbs2-0011" title="KakkoJ , GrönbladhL , SvanborgKD , VonWachenfeldtJ , RückC , RawlingsB , et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry2007;164(5):797‐803. ">Kakko 2007</a>; <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0018" title="LingW , CasadonteP , BeglowG , KampmanKM , PatkarA , BaileyGL , et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA2010;304(14):1576‐83. ">Ling 2010</a>; <a href="./references#CD002207-bbs2-0028" title="SchottenfeldRS , ChawarskiMC , MazlanM . Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double‐blind, placebo‐controlled trial. Lancet2008;371(9631):2192‐200. ">Schottenfeld 2008</a>) or a 1 mg dose of buprenorphine (<a href="./references#CD002207-bbs2-0001" title="AhmadiJ . A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence2002;66(2):111‐4. ">Ahmadi 2002a</a>; <a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). Because of the use of 1 mg buprenorphine as a placebo dose, it is possible that we have underestimated the effect of buprenorphine at active doses. However, the approach is conservative and unlikely to bias results in favour of buprenorphine. </p> <p>The studies selected for this review had two distinct dosing approaches. Eleven studies used flexible dosing (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0019" title="LintzerisN , RitterA , PanjariM , ClarkN , KutinJ , BammerG . Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation trial. American Journal on Addictions2004;13 Suppl 1:S29‐S41. ">Lintzeris 2004</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>; <a href="./references#CD002207-bbs2-0022" title="NeriS , BrunoCM , PulvirentiD , MalaguarneraM , ItalianoC , MauceriB , et al. Randomised clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology2005;179(3):700‐4. ">Neri 2005</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>; <a href="./references#CD002207-bbs2-0029" title="SoykaM , ZinggC , KollerG , KuefnerH . Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome:results form a randomised study. International Journal of Neuropsychopharmacology2008;11(5):641‐53. ">Soyka 2008a</a>;<a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>; <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b</a>) where dose is titrated according to participant preference within a broad upper and lower dose limit. The remaining studies used fixed‐dosing schedules where participants were randomised to receive a fixed dose or a dose with a narrow dose range, without dose adjustment after stabilisation. </p> <p>As most of the studies with fixed‐dosing schedules had more than one dose comparison, we have broadly classified the treatment groups as 'low dose', 'medium dose' and 'high dose' for the respective pharmacotherapy. These categories are arbitrary, driven by the doses used in the studies, and they do not reflect dose equivalence between methadone and buprenorphine. In the case of methadone, dose ranges up to 40 mg were classified as low dose, between 40 mg and 85 mg as medium dose, and more than 85 mg as high dose. In the case of buprenorphine studies where methadone was the comparator, dose ranges for buprenorphine between 2 mg and 6 mg were classified as low dose and between 7 mg and 15 mg as medium dose, and 16 mg as high dose. In the case of the buprenorphine studies where placebo (i.e. 0 mg or 1 mg) is the comparator (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>) we included three buprenorphine dose levels; 0 ‐ 1 mg versus 2 ‐ 6 mg (<a href="./references#CD002207-bbs2-0001" title="AhmadiJ . A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence2002;66(2):111‐4. ">Ahmadi 2002a</a>; <a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>), 0 ‐ 1 mg versus 7 ‐ 15 mg (<a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>), and 0 ‐ 1 mg versus 16 mg (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>; <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). </p> <p>Because of the design of the studies included in the review, we were also able to conduct analyses of: </p> <p> <ul id="CD002207-list-0006"> <li> <p>low‐dose buprenorphine versus low‐dose methadone;</p> </li> <li> <p>low‐dose buprenorphine versus medium‐dose methadone;</p> </li> <li> <p>medium‐dose buprenorphine versus medium‐dose methadone;</p> </li> <li> <p>high‐dose buprenorphine versus high‐dose methadone;</p> </li> <li> <p>buprenorphine (low‐dose, medium‐dose and high‐dose) versus placebo medication.</p> </li> </ul> </p> <p>Again, we used 1 mg of buprenorphine as a placebo dose, as it has been defined in this way by others (<a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>) who refer to this dose as being "adopted to serve essentially as a placebo". </p> <p>The study by <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a> is classified as a flexible‐dose study and we did not include the 20 mg methadone fixed‐dose group from that study in the analyses as we did not choose to compare a low‐dose fixed methadone maintenance treatment (MMT) dose with a flexible buprenorphine maintenance treatment (BMT) dose. Specific study doses are provided in the <a href="./references#CD002207-sec-0121" title="">Characteristics of included studies</a> table. </p> <p>The number of positive urines in each treatment group used to derive the mean number of positive urines with a standard deviation was not available for four studies (<a href="./references#CD002207-bbs2-0013" title="KostenT , SchottenfeldR , ZiedonisD , FalcioniJ . Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease1993;181(6):358‐64. [MEDLINE: 1993274288] ">Kosten 1993</a>; <a href="./references#CD002207-bbs2-0022" title="NeriS , BrunoCM , PulvirentiD , MalaguarneraM , ItalianoC , MauceriB , et al. Randomised clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology2005;179(3):700‐4. ">Neri 2005</a>; <a href="./references#CD002207-bbs2-0023" title="OlivetoAH , FeingoldA , SchottenfeldR , JatlowP , KostenTR . Desipramine in opioid‐dependent cocaine abusers maintained on methadone or buprenorphine. Archives of General Psychiatry1999;56(9):812‐20. ">Oliveto 1999</a>; <a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000</a>), and urine results are therefore not presented for these studies. </p> <p>The reader should be aware that some of the studies used an aqueous ethanol‐based buprenorphine solution which has been reported by some to have a higher bioavailability than the marketed tablet. As the literature on dose equivalence of the solution and the tablet was sparse, and the pharmacodynamics and pharmacokinetics and dosing practices within trials were not well‐articulated, we used the doses as defined by the study authors rather than trying to estimate the dose equivalence per study. It is also noted that intra‐ and inter‐individual differences in metabolism, effects of pregnancy, and concurrent illicit drug use will all affect blood levels of medications. This approach seemed reasonable as no blood levels of the medication were given in the studies. </p> <p>Four studies (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0011" title="KakkoJ , GrönbladhL , SvanborgKD , VonWachenfeldtJ , RückC , RawlingsB , et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry2007;164(5):797‐803. ">Kakko 2007</a>; <a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>) used the buprenorphine‐naloxone formulation. </p> <p> <ul id="CD002207-list-0007"> <li> <p><a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>: fixed high‐dose buprenorphine‐naloxone versus placebo; </p> </li> <li> <p><a href="./references#CD002207-bbs2-0011" title="KakkoJ , GrönbladhL , SvanborgKD , VonWachenfeldtJ , RückC , RawlingsB , et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry2007;164(5):797‐803. ">Kakko 2007</a>: fixed medium‐dose buprenorphine‐naloxone versus placebo; </p> </li> <li> <p><a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>: fixed medium‐dose buprenorphine‐naloxone versus medium‐dose methadone and high‐dose buprenorphine‐naloxone versus high‐dose methadone; </p> </li> <li> <p><a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>: flexible‐dose buprenorphine‐naloxone versus methadone. </p> </li> </ul> </p> <p>We considered empirically testing these four studies separately but they involve different dosing regimens. To be consistent with the analysis in this review where studies were grouped by dosage (both the dose size and whether they are flexible or fixed), we did not combine the buprenorphine‐naloxone studies. The results from all four studies that use the combination formula showed results favouring the buprenorphine‐naloxone combination. </p> </section> <section id="CD002207-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded 36 studies. Four studies (<a href="./references#CD002207-bbs2-0032" title="BickelWK , StitzerML , BigelowGE , LiebsonIA , JasinskiDR , JohnsonRE . A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology and Therapeutics1988;43(1):72‐8. [MEDLINE: 1988081296] ">Bickel 1988</a>; <a href="./references#CD002207-bbs2-0051" title="MeaderN . A comparison of methadone, buprenorphine and alpha2 adrenergic agonists for opioid detoxification: A mixed treatment comparison meta analysis. Drug and Alcohol Dependence2010;108(1‐2):110‐4. ">Meader 2010</a>; <a href="./references#CD002207-bbs2-0057" title="ResnickRB , GalanterM , PychaC , CohenA , GrandisonP , FloodN . Buprenorphine: An alternative to methadone for heroin dependence treatment.. Psychopharmacology Bulletin1992;28(1):109‐13. ">Resnick 1992</a>; <a href="./references#CD002207-bbs2-0067" title="WoodyGE , PooleSA , SubramaniamG , DugoshK , BogenschutzM , AbbottP , et al. Extended vs short‐term buprenorphine‐naloxone for treatment of opioid‐addicted youth: A randomized trial. JAMA2008;300(17):2003‐11. ">Woody 2008</a>) were essentially trials of detoxification or withdrawal. The study of <a href="./references#CD002207-bbs2-0034" title="BouchezJ , BeauverieP , TouzeauD . Substitution with buprenorphine in methadone‐ and morphine sulfate‐dependent patients. Preliminary results. European Addiction Research1998;4(Suppl 1):8‐12. ">Bouchez 1998</a> was a non‐randomised comparison of methadone, buprenorphine and morphine sulphate. <a href="./references#CD002207-bbs2-0038" title="GiacomuzziSM , RiemerY , ErtlM , KemmlerG , RösslerH , HinterhuberH , et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: A health‐related quality of life assessment. Addiction2003;98(5):693‐702. ">Giacomuzzi 2003</a> was an open‐label, non‐randomised comparison of methadone and buprenorphine. Two studies involved treating people with chronic pain and iatrogenic opioid dependence (<a href="./references#CD002207-bbs2-0053" title="NeumannAM , BlondellRD , JaanimägiMS , GiambroneAK , HomishGG , LozanoJR , et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. Journal of Addictive Diseases2013;32(1):68‐78. ">Neumann 2013</a>; <a href="./references#CD002207-bbs2-0066" title="WeissRD , Sharpe PotterJS , FiellinDA , ByrneM , ConneryHS , DickinsonW , et al. Adjunctive counseling during brief and extended buprenorphine‐naloxone treatment for prescription opioid dependence: A 2‐phase randomized controlled trial. Archives of General Psychiatry2011;68(12):1238‐46. ">Weiss 2011</a>). </p> <p>Three studies were trials of dosing schedules (<a href="./references#CD002207-bbs2-0041" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . Buprenorphine treatment of opioid dependence: Clinical trial of daily versus alternate‐day dosing. Drug and Alcohol Dependence1995;40(1):27‐35. ">Johnson 1995b</a>; <a href="./references#CD002207-bbs2-0049" title="MarschLA , BickelWK , BadgerGJ , JacobsEA . Buprenorphine treatment for opioid dependence: relative efficacy of daily, twice and thrice weekly dosing. Drug and Alcohol Dependence2005;77(2):195‐204. ">Marsch 2005</a>; <a href="./references#CD002207-bbs2-0052" title="MontoyaID , GorelickDA , PrestonKL , SchroederJR , UmbrichtA , CheskinLJ , et al. Randomized trial of buprenorphine for treatment of current opiate and cocaine dependence. Clinical Pharmacology and Therapeutics2004;75(1):34‐48. ">Montoya 2004</a>). Three studies were feasibility or efficacy trials that did not report doses or outcome variables of interest (<a href="./references#CD002207-bbs2-0033" title="BondC , MathesonC , LawrieT , CameronI , RobinsonA , McNameeP , et al. A randomised comparison of methadone against buprenorphine in the treatment of opioid dependency: a feasibility study. International Journal of Pharmacy Practice2004;Supplement 2004:R52. ">Bond 2004</a>; <a href="./references#CD002207-bbs2-0037" title="GerraG , BorellaF , ZaimovicA , MoiG , BussandriM , BibiciC , et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug and Alcohol Dependence2004;75(1):37‐45. ">Gerra 2004</a>; <a href="./references#CD002207-bbs2-0060" title="SigmonS , WongC , ChausmerA , LiebsonI , BigelowG . Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction2004;99(11):1439‐49. ">Sigmon 2004</a>). One study was of the transfer to opioid replacement therapy (<a href="./references#CD002207-bbs2-0042" title="JonesHE , JohnsonRE , JasinskiDR , MilioL . Randomised controlled study transitioning opioid‐dependent pregnant women from short‐acting morphine to buprenorphine or methadone. Drug and Alcohol Dependence2005;78(1):33‐8. ">Jones 2005a</a>), and papers by <a href="./references#CD002207-bbs2-0054" title="O'ConnorPG , OlivetoAH , ShiJM , TrifflemanEG , CarrollKM , KostenTR , et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine1998;105(2):100‐5. ">O'Connor 1998</a> and <a href="./references#CD002207-bbs2-0048" title="LucasGM , ChaudryA , HsuJ , WoodsonT , LauB , OlsenY , et al. Clinic‐based treatment of opioid‐dependent HIV‐Infected patients versus referral to an opioid treatment program. A randomized trial. Annals of Internal Medicine2010;152(11):704‐11. ">Lucas 2010</a> were trials of treatment setting, not of medication. Four studies involved pregnant women (<a href="./references#CD002207-bbs2-0036" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: A double‐blind, double‐dummy comparison study. Addiction2006;101(2):275‐81. ">Fischer 2006</a>; <a href="./references#CD002207-bbs2-0043" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid‐dependent patients: Effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1‐10. ">Jones 2005b</a>; <a href="./references#CD002207-bbs2-0045" title="JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone and buprenorphine exposure. New England Journal of Medicine2010;363(24):2320‐2331. ">Jones 2010b</a>). The <a href="./references#CD002207-bbs2-0056" title="PintoH , RumballD , MaskreyV , HollandR . A pilot study for a randomized controlled and patient preference trial of buprenorphine versus methadone maintenance treatment in the management of opiate dependent patients. Journal of Substance Use2008;13(2):73‐82. ">Pinto 2008</a> study was a feasibility trial and no participants were randomised, and the studies by <a href="./references#CD002207-bbs2-0058" title="SacerdoteP , FranchiS , GerraG , LecceseV , PaneraiAE , SomainiL . Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain, Behavior, and Immunity2008;22(4):606‐13. ">Sacerdote 2008</a>, <a href="./references#CD002207-bbs2-0039" title="GryczynskiJ , MitchellSG , JaffeJH , KellySM , MyersCP , O'GradyKE , et al. Retention in methadone and buprenorphine treatment among African Americans. Journal of Substance Abuse Treatment2013;45(3):287‐92. ">Gryczynski 2013</a> and <a href="./references#CD002207-bbs2-0050" title="McKeganeyN , RussellC , CockayneL . Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine‐naloxone) patients compared. Journal of Substance Abuse Treatment2013;44(1):97‐102. ">McKeganey 2013</a> were not randomised trials. </p> <p>The remaining studies were a number of interim reports or secondary analysis of trials already included in this review, and data from only one article for each trial were included in the review (<a href="./references#CD002207-bbs2-0035" title="EderH , FischerG , GombasW , JagschR , StuehlingerG , KasperS . Comparison of buprenorphine and methadone maintenance in opiate addicts. European Addiction Research1998;4(Suppl 1):3‐7. ">Eder 1998</a>; <a href="./references#CD002207-bbs2-0040" title="HarrisAH , GospodarevskayaE , RitterA . A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence. Pharmacoeconomics2005;23(1):77‐91. ">Harris 2005</a>; <a href="./references#CD002207-bbs2-0046" title="KostenT , FalcioniJ , OlivetoA , Feingold , A . Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. American Journal on Addictions2004;13(2):191‐201. ">Kosten 2004</a>; <a href="./references#CD002207-bbs2-0047" title="LottDC , StrainEC , BroonerRK , BIgelowGE , JohnsonRE . HIV risk behaviors during pharmacologic treatment for opioid dependence: A comparison of levomethadyl acetate [corrected], buprenorphine, and methadone. Journal of Substance Abuse Treatment2006;31(2):187‐94. ">Lott 2006</a>; <a href="./references#CD002207-bbs2-0055" title="OlivetoA , KostenT , SchottenfeldR , ZiedonisD , FalcioniJ . Cocaine use in buprenorphine vs methadone maintained patients. American Journal on Addictions1994;3(1):43‐8. ">Oliveto 1994</a>; <a href="./references#CD002207-bbs2-0059" title="SchottenfeldR , PakesJ , KostenT . Prognostic factors in buprenorphine‐ versus methadone‐maintained patients. Journal of Nervous and Mental Disease1998;186(1):35‐43. [MEDLINE: 1998118328] ">Schottenfeld 1998</a>; <a href="./references#CD002207-bbs2-0061" title="SoykaM , LiebM , KagererS , ZinggC , KollerG , LehnertP , et al. Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial. Journal of Clinical Psychopharmacology2008;28(6):699‐703. ">Soyka 2008b</a>; <a href="./references#CD002207-bbs2-0062" title="StineSM , KostenTR . Reduction of opiate withdrawal‐like symptoms by cocaine abuse during methadone and buprenorphine maintenance. Am J Drug Alcohol Abuse1994;20(4):445‐58. [MEDLINE: 1995133568] ">Stine 1994</a>; <a href="./references#CD002207-bbs2-0063" title="StrainEC , StitzerML , LiebsonIA , BigelowGE . Buprenorphine versus methadone in the treatment of opioid dependence: self reports, urinalysis, and addiction severity index. Journal of Clinical Psychopharmacology1996;16(1):58‐67. [MEDLINE: 1996431336] ">Strain 1996</a>; <a href="./references#CD002207-bbs2-0064" title="UehlingerC , DéglonJ , LivotiS , PetitjeanS , WaldvogelD , LadewigD . Comparison of buprenorphine and methadone in the treatment of opioid dependence. Eur Addict Res1998;4 Suppl 1:13‐8. ">Uehlinger 1998</a>; <a href="./references#CD002207-bbs2-0065" title="WardenD , SubramaniamGA , CarmodyT , WoodyGE , MinhajuddinA , PooleSA , et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors2012;37(9):1046‐53. ">Warden 2012</a>). </p> </section> </section> <section id="CD002207-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>See 'Risk of bias' tables in the <a href="./references#CD002207-sec-0121" title="">Characteristics of included studies</a> Table, <a href="#CD002207-fig-0002">Figure 2</a> and <a href="#CD002207-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD002207-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002207-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD002207-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002207-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002207-sec-0052"> <h4 class="title">Allocation</h4> <p>Thirteen studies provided an adequate sequence generation for the randomisation process, including a random number table from a textbook or computer‐generated or the use of sealed envelopes. One study randomised by consecutive numerical order which we considered inadequate (<a href="./references#CD002207-bbs2-0003" title="AhmadiJ , AhmadiK , OhaeriJ . Controlled, randomised trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study. European Journal of Clinical Investigation2003;33(9):824‐9. ">Ahmadi 2003b</a>). The remainder of the trials (n = 17) did not describe the randomisation process in sufficient detail to be clear whether the method was adequate, and are rated as being at unclear risk of bias. </p> <p>Eleven studies provided an adequate method of concealment of allocation, including the use of an independent external agency, often the pharmacy. Nineteen studies did not describe the concealment of allocation process in sufficient detail to be clear that the allocation concealment method was adequate, and are rated as being at unclear risk of bias. One study reported a concealment method defined as inadequate, i.e., at high risk of bias. </p> </section> <section id="CD002207-sec-0053"> <h4 class="title">Blinding</h4> <p>Of the 31 studies included in this review, 22 were reportedly conducted under double‐blind conditions. Ten studies (<a href="./references#CD002207-bbs2-0001" title="AhmadiJ . A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence2002;66(2):111‐4. ">Ahmadi 2002a</a>; <a href="./references#CD002207-bbs2-0003" title="AhmadiJ , AhmadiK , OhaeriJ . Controlled, randomised trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study. European Journal of Clinical Investigation2003;33(9):824‐9. ">Ahmadi 2003b</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004;</a><a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0011" title="KakkoJ , GrönbladhL , SvanborgKD , VonWachenfeldtJ , RückC , RawlingsB , et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomised controlled trial. American Journal of Psychiatry2007;164(5):797‐803. ">Kakko 2007</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0019" title="LintzerisN , RitterA , PanjariM , ClarkN , KutinJ , BammerG . Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation trial. American Journal on Addictions2004;13 Suppl 1:S29‐S41. ">Lintzeris 2004</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>; <a href="./references#CD002207-bbs2-0022" title="NeriS , BrunoCM , PulvirentiD , MalaguarneraM , ItalianoC , MauceriB , et al. Randomised clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology2005;179(3):700‐4. ">Neri 2005;</a><a href="./references#CD002207-bbs2-0029" title="SoykaM , ZinggC , KollerG , KuefnerH . Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome:results form a randomised study. International Journal of Neuropsychopharmacology2008;11(5):641‐53. ">Soyka 2008a</a>) were open comparative trials. All the studies, including the open‐label, have been judged as being at low risk of bias for performance and detection bias because the objective outcomes are considered not to be influenced by lack of blinding. In order to maintain the double‐blind where methadone was compared with buprenorphine, participants were given both an oral solution of either active or placebo methadone syrup and a sublingual preparation of active or placebo buprenorphine (a double‐blind, double‐dummy design). In a few trials the method of maintaining the blinding was not given. Additionally, the success of the blinding was not reported in the trials. </p> </section> <section id="CD002207-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>All the studies have been judged to be at low risk of bias because all used the intention‐to‐treat (ITT) principle. </p> </section> </section> <section id="CD002207-sec-0055"> <h3 class="title" id="CD002207-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD002207-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: comparison between flexible‐dose methadone and buprenorphine</a>; <a href="./full#CD002207-tbl-0002"><b>Summary of findings 2</b> Summary of findings for the comparison between high‐dose buprenorphine and placebo</a> </p> <p>See <a href="./full#CD002207-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD002207-tbl-0002">summary of findings Table 2</a> </p> <section id="CD002207-sec-0056"> <h4 class="title">(01) Retention in treatment:</h4> <section id="CD002207-sec-0057"> <h5 class="title">Comparison 01: Flexible‐dose buprenorphine versus flexible‐dose methadone:</h5> <p>As noted earlier, the flexible‐dose studies probably provide the best estimate of the likely impact of methadone and buprenorphine in day‐to‐day clinical practice, as they mirror clinical practice in terms of dose adjustments and in terms of the doses employed in the studies. The 11 studies (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0019" title="LintzerisN , RitterA , PanjariM , ClarkN , KutinJ , BammerG . Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation trial. American Journal on Addictions2004;13 Suppl 1:S29‐S41. ">Lintzeris 2004</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>; <a href="./references#CD002207-bbs2-0022" title="NeriS , BrunoCM , PulvirentiD , MalaguarneraM , ItalianoC , MauceriB , et al. Randomised clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology2005;179(3):700‐4. ">Neri 2005</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>; <a href="./references#CD002207-bbs2-0061" title="SoykaM , LiebM , KagererS , ZinggC , KollerG , LehnertP , et al. Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial. Journal of Clinical Psychopharmacology2008;28(6):699‐703. ">Soyka 2008b</a>; <a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>; <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b</a>); 1391 participants included in the analysis, showed results in favour of methadone: risk ratio (RR) 0.83; 95% confidence interval (CI) 0.73 to 0.95. The Chi² test for heterogeneity was significant (I² = 56%, P = 0.01). Because of differences in methodology potentially creating heterogeneity among the 11 flexible‐dose studies, we conducted separate meta‐analyses of the double‐blind studies and open‐label studies. The results of these separate analyses indicated that in the double‐blind studies (five studies, 788 participants) there was a lower rate of retention for participants treated with buprenorphine: RR 0.83; 95% CI 0.72 to 0.95, with very little heterogeneity (I² = 19.0%, P = 0.29). However, very high heterogeneity was observed among open‐label studies (six studies, 603 participants; I² = 73%, P &lt; 0.005). The results are presented in <a href="./references#CD002207-fig-0005" title="">Analysis 1.1</a> and <a href="#CD002207-fig-0004">Figure 4</a> </p> <div class="figure" id="CD002207-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Flexible dose buprenorphine versus flexible dose methadone, outcome: 1.1 Retention in treatment." data-id="CD002207-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Flexible dose buprenorphine versus flexible dose methadone, outcome: 1.1 Retention in treatment. </p> </div> </div> </div> </section> <section id="CD002207-sec-0058"> <h5 class="title">Comparison 02: Low‐dose buprenorphine versus low‐dose methadone:</h5> <p>The comparison indicated that low‐dose methadone was more likely to retain participants than low‐dose buprenorphine; RR 0.67; 95% CI 0.52 to 0.87; three studies, 253 participants (<a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0013" title="KostenT , SchottenfeldR , ZiedonisD , FalcioniJ . Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease1993;181(6):358‐64. [MEDLINE: 1993274288] ">Kosten 1993</a>; <a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>). See <a href="./references#CD002207-fig-0011" title="">Analysis 2.1</a>. </p> </section> <section id="CD002207-sec-0059"> <h5 class="title">Comparison 03: Medium‐dose buprenorphine versus medium‐dose methadone:</h5> <p>There was no difference between medium‐dose buprenorphine and medium‐dose methadone in the ability to retain participants in treatment, RR 0.87; 95% CI 0.69 to 1.10; seven studies, 780 participants (<a href="./references#CD002207-bbs2-0007" title="JohnsonR , JaffeJ , FudalaP . A controlled trial of buprenorphine treatment for opioid dependence. JAMA1992;267(20):2750‐5. [MEDLINE: 1992251936] ">Johnson 1992</a>; <a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>; <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>; <a href="./references#CD002207-bbs2-0023" title="OlivetoAH , FeingoldA , SchottenfeldR , JatlowP , KostenTR . Desipramine in opioid‐dependent cocaine abusers maintained on methadone or buprenorphine. Archives of General Psychiatry1999;56(9):812‐20. ">Oliveto 1999</a>; <a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000</a>; <a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>; <a href="./references#CD002207-bbs2-0027" title="SchottenfeldRS , ChawarskiMC , PakesJR , PantalonMV , CarrollKM , KostenTR . Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. American Journal of Psychiatry2005;162(2):340‐9. ">Schottenfeld 2005</a>). See <a href="./references#CD002207-fig-0015" title="">Analysis 3.1</a>. </p> </section> <section id="CD002207-sec-0060"> <h5 class="title">Comparison 04: High‐dose buprenorphine versus high‐dose methadone:</h5> <p>There were no differences between high‐dose buprenorphine and high‐dose methadone in retention: RR 0.79; 95% CI 0.20 to 3.16; one study, 134 participants (<a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>). See <a href="./references#CD002207-fig-0019" title="">Analysis 4.1</a> </p> </section> <section id="CD002207-sec-0061"> <h5 class="title">Comparison 05: Low‐dose buprenorphine maintenance versus placebo:</h5> <p>The results showed a benefit for low‐dose buprenorphine over placebo in terms of retaining participants in treatment: RR 1.50; 95% CI 1.19 to 1.88); five studies, 1131 participants (<a href="./references#CD002207-bbs2-0001" title="AhmadiJ . A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Drug and Alcohol Dependence2002;66(2):111‐4. ">Ahmadi 2002a</a>; <a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). S<i>ee</i><a href="./references#CD002207-fig-0021" title="">Analysis 5.1</a>. </p> </section> <section id="CD002207-sec-0062"> <h5 class="title">Comparison 06: Medium‐dose buprenorphine maintenance versus placebo:</h5> <p>The results showed a benefit for medium‐dose buprenorphine over placebo in terms of retaining participants in treatment: RR 1.74; 95% CI 1.06 to 2.87; four studies, 887 participants (<a href="./references#CD002207-bbs2-0002" title="AhmadiJ . Methadone versus buprenorphine maintenance for the treatment of heroin‐dependent outpatients. Journal of Substance Abuse Treatment2003;24(3):217‐20. ">Ahmadi 2003a</a>; <a href="./references#CD002207-bbs2-0004" title="AhmadiJ , Babaee‐BeigiM , AlishahiM , MaanyI , HidariT . Twelve‐month maintenance treatment of opium‐dependent patients. Journal of Substance Abuse Treatment2004;26(1):61‐4. ">Ahmadi 2004</a>; <a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). S<i>ee</i><a href="./references#CD002207-fig-0025" title="">Analysis 6.1</a>. </p> </section> <section id="CD002207-sec-0063"> <h5 class="title">Comparison 07: High dose buprenorphine maintenance versus placebo:</h5> <p>The results showed a benefit for high‐dose buprenorphine over placebo in terms of retaining participants in treatment: RR 1.82; 95% CI 1.15 to 2.90, five studies, 1001 participants (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>; <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>; <a href="./references#CD002207-bbs2-0018" title="LingW , CasadonteP , BeglowG , KampmanKM , PatkarA , BaileyGL , et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA2010;304(14):1576‐83. ">Ling 2010</a>). S<i>ee</i><a href="./references#CD002207-fig-0029" title="">Analysis 7.1</a>. </p> </section> </section> <section id="CD002207-sec-0064"> <h4 class="title">(02) Use of opioids (urinalysis):</h4> <section id="CD002207-sec-0065"> <h5 class="title">Comparison 01: Flexible‐dose buprenorphine versus flexible‐dose methadone:</h5> <p>There was no difference between the two interventions in terms of heroin use, based on results of morphine urinalysis: SMD ‐0.11; 95% CI ‐0.23 to 0.02; eight studies, 1027 participants (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>; <a href="./references#CD002207-bbs2-0029" title="SoykaM , ZinggC , KollerG , KuefnerH . Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome:results form a randomised study. International Journal of Neuropsychopharmacology2008;11(5):641‐53. ">Soyka 2008a</a>; <a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>; <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b</a>; ). <i>S</i>ee <a href="./references#CD002207-fig-0006" title="">Analysis 1.2</a>. </p> </section> <section id="CD002207-sec-0066"> <h5 class="title">Comparison 02: Low‐dose buprenorphine versus low‐dose methadone:</h5> <p>We found no differences in morphine‐positive urine; SMD ‐0.35; 95% CI ‐0.87 to 0.16; one study, 59 participants (<a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>) <i>. S</i>ee <a href="./references#CD002207-fig-0012" title="">Analysis 2.2</a>. </p> </section> <section id="CD002207-sec-0067"> <h5 class="title">Comparison 03: Medium‐dose buprenorphine versus medium‐dose methadone:</h5> <p>We found no difference between medium‐dose buprenorphine and medium‐dose methadone in terms of heroin use, based on results of morphine urinalysis: SMD 0.25; 95% CI ‐0.08 to 0.58; four studies, 476 participants (<a href="./references#CD002207-bbs2-0007" title="JohnsonR , JaffeJ , FudalaP . A controlled trial of buprenorphine treatment for opioid dependence. JAMA1992;267(20):2750‐5. [MEDLINE: 1992251936] ">Johnson 1992</a>; <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>; <a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>; <a href="./references#CD002207-bbs2-0027" title="SchottenfeldRS , ChawarskiMC , PakesJR , PantalonMV , CarrollKM , KostenTR . Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. American Journal of Psychiatry2005;162(2):340‐9. ">Schottenfeld 2005</a>). Se<i>e</i><a href="./references#CD002207-fig-0016" title="">Analysis 3.2</a>. </p> </section> <section id="CD002207-sec-0068"> <h5 class="title">Comparison 04: High‐dose buprenorphine versus high‐dose methadone:</h5> <p>No studies reporting urine data.</p> </section> <section id="CD002207-sec-0069"> <h5 class="title">Comparison 05: Low‐dose buprenorphine maintenance versus placebo:</h5> <p>We found no difference between low‐dose buprenorphine and placebo as indexed by morphine‐positive urines: SMD 0.10; 95% CI ‐0.80 to 1.01; two studies, 487 participants (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). See <a href="./references#CD002207-fig-0022" title="">Analysis 5.2</a>. </p> </section> <section id="CD002207-sec-0070"> <h5 class="title">Comparison 06: Medium‐dose buprenorphine maintenance versus placebo:</h5> <p>We found no difference between medium‐dose buprenorphine and placebo in terms of heroin use as indexed by morphine‐positive urines: SMD ‐0.08; 95% CI ‐0.78 to 0.62; two studies, 463 participants (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>) . See <a href="./references#CD002207-fig-0026" title="">Analysis 6.2</a>. </p> </section> <section id="CD002207-sec-0071"> <h5 class="title">Comparison 07: High‐dose buprenorphine maintenance versus placebo:</h5> <p>Participants on high‐dose buprenorphine treatment had less heroin use as indexed by morphine‐positive urines than those on placebo: SMD ‐1.17; 95% CI ‐1.85 to ‐0.49; three studies, 729 participants (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). See <a href="./references#CD002207-fig-0030" title="">Analysis 7.2</a>. </p> </section> </section> <section id="CD002207-sec-0072"> <h4 class="title">(03) Use of opioids (self‐reported):</h4> <section id="CD002207-sec-0073"> <h5 class="title">Comparison 01: Flexible‐dose buprenorphine versus flexible‐dose methadone:</h5> <p>We found no difference between the two interventions in terms of self‐reported heroin use: SMD ‐0.11; 95% CI ‐0.28 to 0.07; four studies, 501 participants (<a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0019" title="LintzerisN , RitterA , PanjariM , ClarkN , KutinJ , BammerG . Implementing buprenorphine treatment in community settings in Australia: Experiences from the buprenorphine implementation trial. American Journal on Addictions2004;13 Suppl 1:S29‐S41. ">Lintzeris 2004</a>; <a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>). See <a href="./references#CD002207-fig-0007" title="">Analysis 1.3</a>. </p> </section> <section id="CD002207-sec-0074"> <h5 class="title">Comparison 02: Low‐dose buprenorphine versus low‐dose methadone:</h5> <p>There was no difference between low‐dose buprenorphine and low‐dose methadone in self‐reported heroin use: SMD ‐0.29; 95% CI ‐0.38 to 0.96; one study, 37 participants (<a href="./references#CD002207-bbs2-0013" title="KostenT , SchottenfeldR , ZiedonisD , FalcioniJ . Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Disease1993;181(6):358‐64. [MEDLINE: 1993274288] ">Kosten 1993</a>). See <a href="./references#CD002207-fig-0013" title="">Analysis 2.3</a>. </p> </section> <section id="CD002207-sec-0075"> <h5 class="title">Comparison 03: Medium‐dose buprenorphine versus medium‐dose methadone:</h5> <p>There was no difference in self‐reported heroin use between medium doses of buprenorphine and methadone, but again the Chi² test for heterogeneity was significant (P = 0.006): SMD ‐0.82; 95% CI ‐1.83 to 0.19; two studies, 174 participants (<a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>; <a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000</a>). See <a href="./references#CD002207-fig-0017" title="">Analysis 3.3</a>. </p> </section> <section id="CD002207-sec-0076"> <h5 class="title">Comparison 04: High‐dose buprenorphine versus high‐dose methadone:</h5> <p>We found no differences between high‐dose buprenorphine and high‐dose methadone in self‐reported heroin use: SMD ‐0.73; 95% CI ‐1.08 to ‐0.37; one study, 134 participants (<a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>). See <a href="./references#CD002207-fig-0020" title="">Analysis 4.2</a>. </p> <p>Theree were no data on self‐reported heroin use for the remaining comparisons.</p> </section> </section> <section id="CD002207-sec-0077"> <h4 class="title">(04) Use of cocaine:</h4> <section id="CD002207-sec-0078"> <h5 class="title">Comparison 01: Flexible‐dose buprenorphine versus flexible‐dose methadone:</h5> <p>We found no difference between six studies of flexible dosing with buprenorphine or methadone for cocaine‐positive urines; SMD 0.10; 95% CI ‐0.05 to 0.25; 929 participants (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a><a href="./references#CD002207-bbs2-0029" title="SoykaM , ZinggC , KollerG , KuefnerH . Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome:results form a randomised study. International Journal of Neuropsychopharmacology2008;11(5):641‐53. ">Soyka 2008a</a>; <a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>l <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b</a>). Se<i>e</i><a href="./references#CD002207-fig-0008" title="">Analysis 1.4</a>. </p> </section> <section id="CD002207-sec-0079"> <h5 class="title">Comparison 02: Low‐dose buprenorphine versus low‐dose methadone:</h5> <p>There were no differences in cocaine‐positive urines between low‐dose usage of buprenorphine and methadone; SMD 0.08; 95% CI ‐0.43 to 0.59; one study, 59 participants (<a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>). See <a href="./references#CD002207-fig-0014" title="">Analysis 2.4</a>. </p> </section> <section id="CD002207-sec-0080"> <h5 class="title">Comparison 03: Medium‐dose buprenorphine versus medium‐dose methadone:</h5> <p>We found no difference between medium dosage of buprenorphine and methadone for cocaine‐positive urines: SMD 0.21; 95% CI ‐0.06 to 0.47; two studies, 57 participants (<a href="./references#CD002207-bbs2-0026" title="SchottenfeldRS , PakesJR , OlivetoA , ZiedonisD , KostenTR . Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry1997;54(8):713‐20. [MEDLINE: 1997429160] ">Schottenfeld 1997</a>; <a href="./references#CD002207-bbs2-0027" title="SchottenfeldRS , ChawarskiMC , PakesJR , PantalonMV , CarrollKM , KostenTR . Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. American Journal of Psychiatry2005;162(2):340‐9. ">Schottenfeld 2005</a>). See <a href="./references#CD002207-fig-0018" title="">Analysis 3.4</a>. </p> </section> <section id="CD002207-sec-0081"> <h5 class="title">Comparison 4: High‐dose buprenorphine versus high‐dose methadone:</h5> <p>There were no data for this comparison on cocaine‐positive urines.</p> </section> <section id="CD002207-sec-0082"> <h5 class="title">Comparison 05: Low‐dose buprenorphine maintenance versus placebo:</h5> <p>We found no difference between low‐dose buprenorphine and placebo for cocaine‐positive urines: SMD 0.26; 95% CI ‐0.10 to 0.62; one study, 120 participants (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>). See <a href="./references#CD002207-fig-0023" title="">Analysis 5.3</a>. </p> </section> <section id="CD002207-sec-0083"> <h5 class="title">Comparison 06: Medium‐dose buprenorphine maintenance versus placebo:</h5> <p>There was an advantage for placebo over medium‐dose buprenorphine for cocaine‐positive urines: SMD 0.50; 95% CI 0.05 to 0.94; one study, 90 participants (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>). See <a href="./references#CD002207-fig-0027" title="">Analysis 6.3</a>. </p> </section> <section id="CD002207-sec-0084"> <h5 class="title">Comparison 07: High‐dose buprenorphine maintenance versus placebo:</h5> <p>We found no difference between high‐dose buprenorphine and placebo for cocaine‐positive urines: SMD 0.08; 95% CI ‐0.16 to 0.32; one study, 296 participants (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>). See <a href="./references#CD002207-fig-0031" title="">Analysis 7.3</a>. </p> </section> </section> <section id="CD002207-sec-0085"> <h4 class="title">(05) Use of benzodiazepines:</h4> <section id="CD002207-sec-0086"> <h5 class="title">Comparison 01: Flexible‐dose buprenorphine versus flexible‐dose methadone:</h5> <p>We found no difference across six studies comparing flexible dosing of buprenorphine and methadone for benzodiazepine‐positive urines: SMD 0.05; 95% CI ‐0.12 to 0.22; 859 participants (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0014" title="KristensenØ , EspegrenO , AslandR , JakobsenE , LieØ , SeilerS . Buprenorphine and methadone to opiate addicts‐‐a randomized trial (English abstract only). Tidsskrift for den Norske Laegeforening2005;125(2):148‐51. [PMID: 15665884] ">Kristensen 2005</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>; <a href="./references#CD002207-bbs2-0029" title="SoykaM , ZinggC , KollerG , KuefnerH . Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome:results form a randomised study. International Journal of Neuropsychopharmacology2008;11(5):641‐53. ">Soyka 2008a</a>; <a href="./references#CD002207-bbs2-0030" title="StrainE , StitzerM , LiebsonI , BigelowG . Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry1994;151(7):1025‐30. [MEDLINE: 1994279720] ">Strain 1994a</a>; <a href="./references#CD002207-bbs2-0031" title="StrainE , StitzerM , LiebsonI , BigelowG . Buprenorphine versus methadone in the treatment of opioid dependent cocaine users. Psychopharmocology1994;116(4):401‐6. [MEDLINE: 1995215552] ">Strain 1994b</a>).<i>See</i><a href="./references#CD002207-fig-0009" title="">Analysis 1.5</a>. </p> </section> <section id="CD002207-sec-0087"> <h5 class="title">Comaprison 02: Low‐dose buprenorphine versus low‐dose methadone:</h5> <p>No data available for benzodiazepine‐positive urines.</p> </section> <section id="CD002207-sec-0088"> <h5 class="title">Comparison 03: medium‐dose buprenorphine versus medium‐dose methadone:</h5> <p>No data available for benzodiazepine‐positive urines.</p> </section> <section id="CD002207-sec-0089"> <h5 class="title">Comparison 04: high‐dose buprenorphine versus high‐dose methadone:</h5> <p>No data available for benzodiazepine‐positive urines.</p> </section> <section id="CD002207-sec-0090"> <h5 class="title">Comparison 05: Low‐dose buprenorphine maintenance versus placebo:</h5> <p>We found no difference between low‐dose buprenorphine and placebo for benzodiazepine‐positive urines: SMD 0.03; 95% CI ‐0.33 to 0.38; one study, 120 participants (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>). See <a href="./references#CD002207-fig-0024" title="">Analysis 5.4</a>. </p> </section> <section id="CD002207-sec-0091"> <h5 class="title">Comparison 06: Medium‐dose buprenorphine maintenance versus placebo:</h5> <p>Buprenorphine was superior to placebo for benzodiazepine‐positive urines; SMD ‐0.81; 95% CI ‐1.27 to ‐0.36; one study, 90 participants (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>). See <a href="./references#CD002207-fig-0028" title="">Analysis 6.4</a>. </p> </section> <section id="CD002207-sec-0092"> <h5 class="title">Comparison 07: High‐dose buprenorphine maintenance versus placebo:</h5> <p>We found no difference between high‐dose buprenorphine and placebo for benzodiazepine‐positive urines: SMD ‐1.65; 95% CI ‐4.94 to 1.65; two studies, 336 participants (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>). See <a href="./references#CD002207-fig-0032" title="">Analysis 7.4</a>. </p> </section> </section> <section id="CD002207-sec-0093"> <h4 class="title">(06) Criminal activity:</h4> <section id="CD002207-sec-0094"> <h5 class="title">Comparison 01: Flexible‐dose buprenorphine versus flexible‐dose methadone:</h5> <p>We found no difference between the buprenorphine and methadone groups: SMD ‐0.10; 95% CI ‐0.31 to 0.12; two studies, 328 participants (<a href="./references#CD002207-bbs2-0020" title="MaguraS , LeeJD , HershbergerJ , JosephH , MarschL , ShropshireC , et al. Buprenorphine and methadone maintenance in jail and post‐release: A randomized clinical trial. Drug and Alcohol Dependence2009;99(1‐3):222‐30. ">Magura 2009</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>). See <a href="./references#CD002207-fig-0010" title="">Analysis 1.6</a>. </p> <p>For the other comparisons, no data on criminal activity were reported in the included studies. </p> </section> </section> <section id="CD002207-sec-0095"> <h4 class="title">(07) Mortality:</h4> <p>Five studies provided mortality data (<a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>; <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>; <a href="./references#CD002207-bbs2-0028" title="SchottenfeldRS , ChawarskiMC , MazlanM . Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double‐blind, placebo‐controlled trial. Lancet2008;371(9631):2192‐200. ">Schottenfeld 2008</a>). No deaths were reported in the <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a> or <a href="./references#CD002207-bbs2-0028" title="SchottenfeldRS , ChawarskiMC , MazlanM . Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double‐blind, placebo‐controlled trial. Lancet2008;371(9631):2192‐200. ">Schottenfeld 2008</a> studies. <a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a> reported a 20% mortality in control participants at one year while the <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>study reported two deaths unrelated to the study medication (i.e., stab wounds and cancer). </p> <p><b>(08) Adverse events:</b> </p> <p>Ten studies report collecting data on adverse events or side effects (<a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a>; <a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>; <a href="./references#CD002207-bbs2-0012" title="KamienJB , BranstetterSA , AmassL . Buprenorphine‐naloxone versus methadone maitenance therapy: A randomised double‐blind trial with opioid dependent patients. Heroin Addiction and Related Clinical Problems2008;10(4):5‐18. ">Kamien 2008</a>; <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a>; <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>; <a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>; <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>; <a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>; <a href="./references#CD002207-bbs2-0061" title="SoykaM , LiebM , KagererS , ZinggC , KollerG , LehnertP , et al. Cognitive functioning during methadone and buprenorphine treatment: Results of a randomized clinical trial. Journal of Clinical Psychopharmacology2008;28(6):699‐703. ">Soyka 2008b</a>).The frequency and types of adverse events varied by study. There were no attempts to compare the adverse events statistically in <a href="./references#CD002207-bbs2-0021" title="MattickRP , AliR , WhiteJ , O'BrienS , WolkS , DanzC . Buprenorphine versus methadone maintenance therapy: A randomised double‐blind with 405 opioid‐dependent patients. Addiction2003;98(4):441‐52. ">Mattick 2003</a>, <a href="./references#CD002207-bbs2-0006" title="FudalaPJ , BridgeTP , HerbertS , WillifordWO , ChiangCN , JonesK , et al. Office‐based treatment of opiate addiction with a sublingual‐tablet formulation of buprenorphine and naloxone. New England Journal of Medicine2003;349(10):949‐58. ">Fudala 2003</a> or <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a>. <a href="./references#CD002207-bbs2-0016" title="LingW , WessonD , CharuvastraC , KlettJ . A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry1996;53(5):401‐7. [MEDLINE: 1996212784] ">Ling 1996</a> reported there were "numerous and diverse adverse events reported for both groups" and "adverse events equally represented in all groups" (<a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). Those studies that did compare adverse events statistically found no difference between groups in the frequency of adverse events (<a href="./references#CD002207-bbs2-0024" title="PaniPP , MaremmaniI , PirastuR , TagliamonteA , GessaGL . Buprenorphine: A controlled trial in the treatment of opioid dependence. Drug and Alcohol Dependence2000;60(1):39‐50. ">Pani 2000</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>). The methadone group in <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a> reported significantly more sedation (58% versus 26%). <a href="./references#CD002207-bbs2-0015" title="KrookAL , BrørsO , DahlbergJ , GrouffK , MagnusP , RøysambE , et al. A placebo‐controlled study of high dose buprenorphine in opiate dependents waiting for medication‐assisted rehabilitation in Oslo, Norway. Addiction2002;97(5):533‐42. ">Krook 2002</a> reported that the two groups were statistically similar, with the exception that more of the placebo group reported exanthema. The side effects were reportedly "similar among groups" (<a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002207-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002207-sec-0096"></div> <section id="CD002207-sec-0097"> <h3 class="title" id="CD002207-sec-0097">Summary of main results</h3> <p>Buprenorphine is an effective medication for maintenance treatment of opioid dependence, as it is superior to placebo in retaining people in treatment based on all the 14 placebo‐controlled comparisons. However, based on objective urinanalysis results, buprenorphine is only superior to placebo in suppression of heroin use at high doses (defined here as 16 mg or more) but not at low or medium doses (defined here as 15 mg or less). </p> <p>Before discussing the results of the buprenorphine and methadone comparisons, we remind the reader that we have distinguished between the fixed‐dose studies and flexible‐dose studies, as the former do not relate to clinical reality, where doses are in fact titrated by the clinician in response to individual need. The flexible‐dose studies are more clinically relevant and deserve more attention in consideration of the meta‐analytic review findings. The results of the meta‐analyses here clearly indicate that methadone is better able to retain participants than buprenorphine in flexible‐dosing approaches (at least in the double‐blind efficacy trials). Turning to reduction in heroin use, within the flexible‐dose studies, there was no evidence of any difference between methadone and buprenorphine in their ability to suppress heroin use (self‐reported or urinanalysis results). </p> <p>One explanation which has been advanced by authors in some of the studies included here for the poorer retention in buprenorphine treatment (<a href="./references#CD002207-bbs2-0005" title="FischerG , GombasW , EderH , JagschR , PeternellA , StuhlingerG , et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction1999;94(9):1337‐47. ">Fischer 1999</a>; <a href="./references#CD002207-bbs2-0025" title="PetitjeanS , StohlerR , DéglonJJ , LivotiS , WaldvogelD , UehlingerC , et al. Double‐blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence2001;62(1):97‐104. ">Petitjean 2001</a>) is that they inducted participants too slowly onto buprenorphine, and that this was the cause of the poorer retention in that medication group. It is possible that retention is affected by too‐slow induction, and given the apparent relative safety of buprenorphine it may be possible to induct people to higher doses at a more rapid rate and to overcome the problem of slightly poorer retention for buprenorphine compared with methadone. However, there are a number of other possible explanations for the poorer retention on buprenorphine than methadone. In particular, it may well be that buprenorphine, being a partial agonist, does not retain people because it does not have a full opioid effect and is less satisfying to those allocated to it. Another possibility is that people in the initial stages of dosing who have recently ingested heroin suffer a mild withdrawal syndrome by virtue of buprenorphine (a partial agonist) displacing heroin (a full agonist) from opioid receptors in the central nervous system, and this mild withdrawal may lead to leaving treatment. A further possibility is that buprenorphine is simply easier to withdraw from and, on that basis, those using it are more at liberty to leave treatment without the severe withdrawal syndrome that can accompany methadone withdrawal. These factors may all act together to cause buprenorphine to have a slightly poorer outcome for retention than methadone. Future research should be undertaken to address this particular issue. </p> <p>Turning to other outcomes, the results from two trials suggest there is no difference between methadone and buprenorphine for reducing criminal activity. There is evidence from other literature showing criminal activity is decreased in those who are in methadone treatment (<a href="./references#CD002207-bbs2-0085" title="LindB , ChenS , WeatherburnD , MattickR . The effectiveness of methadone maintenance treatment in controlling crime. An Australian aggregate‐level analysis. Journal of Criminology2005;45(2):201‐11. ">Lind 2005</a>). The majority of the studies that reported mortality data reported no deaths, and the two studies that reported deaths were among the controls (<a href="./references#CD002207-bbs2-0010" title="KakkoJ , SvanborgKD , KreekMJ , HeiligM . 1‐year retention and social function after buprenorphine‐assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo‐controlled trial. Lancet2003;361(9358):662‐8. ">Kakko 2003</a>) or not related to study medication (<a href="./references#CD002207-bbs2-0017" title="LingW , CharuvastraC , CollinsJF , BatkiS , BrownLSJr , KintaudiP , et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomised clinical trial. Addiction1998;93(4):475‐86. ">Ling 1998</a>). Other research suggests that mortality is decreased among those in opioid substitution treatment (<a href="./references#CD002207-bbs2-0094" title="SoykaM , TräderA , KlotscheJ , BackmundM , BühringerG , RehmJ , et al. Six‐year mortality rates of patients in methadone and buprenorphine maintenance therapy: results form a nationally representative cohort study. Journal of Clinical Psychopharmacology2011;31(5):678‐80. ">Soyka 2011</a>), although methadone dosing in the first two weeks of induction is associated with heightened risk of death from methadone overdose (<a href="./references#CD002207-bbs2-0072" title="ClausenT , AnchersenK , WaalH . Mortality prior to, during and after opioid maintenance treatment (OMT): A national prospective cross‐registry study. Drug and Alcohol Dependence2008;94(1‐3):151‐7. ">Clausen 2008</a>; <a href="./references#CD002207-bbs2-0074" title="DegenhardtL , RandallD , HallW , LawM , ButlerT , BurnsL . Mortality among clients of a state‐wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug and Alcohol Dependence2009;105(1‐2):9‐15. ">Degenhardt 2009</a>; <a href="./references#CD002207-bbs2-0075" title="DegenhardtL , BucelloC , MathersB , BrieglebC , AliH , HickmanM , et al. Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta‐analysis of cohort studies. Addiction2011;106(1):32‐51. ">Degenhardt 2011</a>; <a href="./references#CD002207-bbs2-0081" title="GibsonA , DegenhardtL , MattickRP , AliR , WhiteJ , O'BrienS . Exposure to opioid maintenance treatment reduces long‐term mortality. Addiction2008;103(3):462‐8. ">Gibson 2008</a>). </p> <p>The majority of studies did not compare adverse events statistically, although those that did found only one difference between methadone and buprenorphine with one study reporting more sedation among participants on methadone (<a href="./references#CD002207-bbs2-0009" title="JohnsonRE , ChutuapeMA , Strain , EC , WalshSL , StitzerML , BegelowGE . A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine2000;343(18):1290‐7. ">Johnson 2000</a>). </p> </section> <section id="CD002207-sec-0098"> <h3 class="title" id="CD002207-sec-0098">Overall completeness and applicability of evidence</h3> <p>The evidence is reasonably complete with regard to the effectiveness of buprenorphine relative to placebo, and buprenorphine relative to methadone, in maintenance for the important outcomes of retention and illicit opioid use. More data on the impacts on criminal activity, mortality and adverse events would be desirable. However, it may not be possible to generate such data from randomised trials, especially for impacts on crime and mortality, as randomised controlled trials are typically too short in duration to show differential effects in these domains. </p> </section> <section id="CD002207-sec-0099"> <h3 class="title" id="CD002207-sec-0099">Quality of the evidence</h3> <p>The clinical trials represented in this review are of reasonable quality, and whilst many of them did not fully explain how randomisation was concealed, they appear to have used doses which are clinically relevant and to have treated participants for significant periods of time. Moreover, despite the tendency of randomised studies to include selected populations, characteristics of drug users enrolled in the studies included in this review appear to be heterogeneous enough to allow generalisability of the results across different clinical and cultural settings. Based on the nature of the trials, it would appear the external validity or generalisability of the results is quite good, particularly from those trials which have used large sample sizes and adequate doses. </p> </section> <section id="CD002207-sec-0100"> <h3 class="title" id="CD002207-sec-0100">Potential biases in the review process</h3> <p>To overcome bias at the study level, we have used: (a) predetermined main outcomes; (b) the main outcomes being independent of the study reporting; (c) including all the reported main outcomes from the studies; and (d) additional data from the authors (which was generally provided). </p> <p>At the review level, to reduce our risks of bias, we (a) used predetermined study inclusion criteria; (b) employed wide‐ranging and thorough searches of the literature; (c) relied on independent coding of the data, with separate resolution of disagreements; and (d) subjected the review to repeated independent refereeing and comment through Cochrane Collaboration methods. For example, as mentioned above, we addressed the potential problem of selective outcome reporting by contacting the authors of the studies to obtain results for main outcome variables. We note that we have reported data for retention for all but one study (<a href="./references#CD002207-bbs2-0008" title="JohnsonRE , EissenbergT , StitzerML , StrainEC , LiebsonIA , BigelowGE . A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence1995;40(1):17‐25. ">Johnson 1995a</a>), where retention was reported by dose change and not by remaining in the treatment condition. There is no evidence of selective reporting for the retention measure. The data for urine results were included, after we asked authors to provide such data and there was good compliance with this request, so that measured outcomes were provided to us and included in the review. </p> <p>We have also included in the review an indication of which studies contributed data to the outcomes, for the interested reader (see Figures and Tables, Data Analysis, and elsewhere in text). </p> </section> <section id="CD002207-sec-0101"> <h3 class="title" id="CD002207-sec-0101">Agreements and disagreements with other studies or reviews</h3> <p>Similar conclusions have been reached by other meta‐analytic reviews of these treatments (<a href="./references#CD002207-bbs2-0070" title="BarnettPG , RodgersJH , BlochD . A meta‐analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction2001;96(5):683‐90. ">Barnett 2001</a>; <a href="./references#CD002207-bbs2-0073" title="ConnockM , Juarez‐GarciaA , JowettS , FrewE , LiuZ , TaylorRJ , et al. Methadone and buprenorphine for the management of opioid dependence; a systematic review and economic evaluation. Health Technology Assessment2007;11(9):1‐190. ">Connock 2007</a>; <a href="./references#CD002207-bbs2-0096" title="WestS , O'NealK , GrahamC . A meta‐analysis comparing the effectiveness of buprenorphine and methadone. Journal of Substance Abuse2000;12(4):405‐14. ">West 2000</a>), and the dose‐response of methadone is well‐established (<a href="./references#CD002207-bbs2-0079" title="FaggianoF , Vigna‐TagliantiF , VersinoE , LemmaP . Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD002208] ">Faggiano 2003</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002207-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002207-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002207-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002207-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Flexible dose buprenorphine versus flexible dose methadone, outcome: 1.1 Retention in treatment." data-id="CD002207-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Flexible dose buprenorphine versus flexible dose methadone, outcome: 1.1 Retention in treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 1 Retention in treatment." data-id="CD002207-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 1 Retention in treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 2 Morphine‐positive urines." data-id="CD002207-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 2 Morphine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 3 Self‐reported heroin use." data-id="CD002207-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 3 Self‐reported heroin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 4 Cocaine‐positive urines." data-id="CD002207-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 4 Cocaine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 5 Benzodiazepine‐positive urines." data-id="CD002207-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 5 Benzodiazepine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 6 Criminal activity." data-id="CD002207-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Flexible‐dose buprenorphine versus flexible‐dose methadone, Outcome 6 Criminal activity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 1 Retention in treatment." data-id="CD002207-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 1 Retention in treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 2 Morphine‐positive urines." data-id="CD002207-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 2 Morphine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 3 Self‐reported heroin use." data-id="CD002207-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 3 Self‐reported heroin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 4 Cocaine‐positive urines." data-id="CD002207-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Low‐dose buprenorphine versus low‐dose methadone, Outcome 4 Cocaine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 1 Retention in treatment." data-id="CD002207-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 1 Retention in treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 2 Morphine‐positive urines." data-id="CD002207-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 2 Morphine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 3 Self‐reported heroin use." data-id="CD002207-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 3 Self‐reported heroin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 4 Cocaine‐positive urines." data-id="CD002207-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Medium‐dose buprenorphine versus medium‐dose methadone, Outcome 4 Cocaine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High‐dose buprenorphine versus high‐dose methadone, Outcome 1 Retention in treatment." data-id="CD002207-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 High‐dose buprenorphine versus high‐dose methadone, Outcome 1 Retention in treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High‐dose buprenorphine versus high‐dose methadone, Outcome 2 Self‐reported heroin use." data-id="CD002207-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 High‐dose buprenorphine versus high‐dose methadone, Outcome 2 Self‐reported heroin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 1 Retention in treatment." data-id="CD002207-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 1 Retention in treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 2 Morphine‐positive urines." data-id="CD002207-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 2 Morphine‐positive urines.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 3 Cocaine‐positive urines." data-id="CD002207-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 3 Cocaine‐positive urines.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 4 Benzodiazepine‐positive urines." data-id="CD002207-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Low‐dose buprenorphine versus placebo, Outcome 4 Benzodiazepine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 1 Retention in treatment." data-id="CD002207-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 1 Retention in treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 2 Morphine‐positive urines." data-id="CD002207-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 2 Morphine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 3 Cocaine‐positive urines." data-id="CD002207-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 3 Cocaine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 4 Benzodiazepine‐positive urines." data-id="CD002207-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Medium‐dose buprenorphine versus placebo, Outcome 4 Benzodiazepine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 High‐dose buprenorphine versus placebo, Outcome 1 Retention in treatment." data-id="CD002207-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 High‐dose buprenorphine versus placebo, Outcome 1 Retention in treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 High‐dose buprenorphine versus placebo, Outcome 2 Morphine‐positive urines." data-id="CD002207-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 High‐dose buprenorphine versus placebo, Outcome 2 Morphine‐positive urines.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 High‐dose buprenorphine versus placebo, Outcome 3 Cocaine‐positive urines." data-id="CD002207-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 High‐dose buprenorphine versus placebo, Outcome 3 Cocaine‐positive urines.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002207-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/urn:x-wiley:14651858:media:CD002207:CD002207-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_t/tCD002207-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 High‐dose buprenorphine versus placebo, Outcome 4 Benzodiazepine‐positive urines." data-id="CD002207-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 High‐dose buprenorphine versus placebo, Outcome 4 Benzodiazepine‐positive urines. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/media/CDSR/CD002207/image_n/nCD002207-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002207-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: comparison between flexible‐dose methadone and buprenorphine</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Buprenorphine maintenance compared with methadone maintenance for opioid dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> People with opioid dependence. </p> <p><b>Settings:</b> Inpatient and outpatient </p> <p><b>Intervention:</b> Buprenorphine maintenance at flexible doses </p> <p><b>Comparison:</b> Methadone maintenance at flexible doses </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Retention in treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 0.83</p> <p>(0.73 to 0.95)*</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 (1391);</p> <p>5 double‐blind (788)</p> <p>6 open‐label (603)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater retention in the methadone group.</p> <p>* the heterogeneity is significant.</p> <p>When the double‐blind studies are analysed separately the heterogeneity is not significant and the RR is 0.83 (0.72 to 0.95) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morphine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.11</p> <p>(‐0.23 to 0.02)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 (1027)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported heroin use</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.11</p> <p>(‐0.28 to 0.07)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 (501)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cocaine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.10</p> <p>(‐0.05 to 0.25)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 (919)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.05</p> <p>(‐0.09 to 0.18]</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 (859)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; SMD: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: comparison between flexible‐dose methadone and buprenorphine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002207-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for the comparison between high‐dose buprenorphine and placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Buprenorphine maintenance compared with methadone maintenance for opioid dependence</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> People with opioid dependence. </p> <p><b>Settings:</b> Inpatient and outpatient </p> <p><b>Intervention:</b> Buprenorphine maintenance at high doses (16 mg) </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Retention in treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 1.82</p> <p>(1.15 to 2.90)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1001 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater retention in buprenorphine group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Morphine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.17</p> <p>(‐1.85 to ‐0.49)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>729 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fewer morphine‐positive urines in buprenorphine group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Benzodiazepine‐positive urines</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD ‐1.65</p> <p>(‐4.94 to 1.65)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>336 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; SMD: standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for the comparison between high‐dose buprenorphine and placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/full#CD002207-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002207-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Flexible‐dose buprenorphine versus flexible‐dose methadone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.73, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Double‐blind flexible dose studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Open label flexible dose studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Morphine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.23, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Self‐reported heroin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.28, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cocaine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.05, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Benzodiazepine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.12, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Criminal activity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.31, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Flexible‐dose buprenorphine versus flexible‐dose methadone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002207-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Low‐dose buprenorphine versus low‐dose methadone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.52, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Morphine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Self‐reported heroin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cocaine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Low‐dose buprenorphine versus low‐dose methadone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002207-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Medium‐dose buprenorphine versus medium‐dose methadone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.69, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Morphine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.08, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Self‐reported heroin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.82 [‐1.83, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cocaine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.06, 0.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Medium‐dose buprenorphine versus medium‐dose methadone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002207-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">High‐dose buprenorphine versus high‐dose methadone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Self‐reported heroin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">High‐dose buprenorphine versus high‐dose methadone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002207-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Low‐dose buprenorphine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.19, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Morphine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.80, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cocaine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Low‐dose buprenorphine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002207-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Medium‐dose buprenorphine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.06, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Morphine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.78, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cocaine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Medium‐dose buprenorphine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002207-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">High‐dose buprenorphine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Retention in treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.15, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Morphine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.17 [‐1.85, ‐0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cocaine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Benzodiazepine‐positive urines <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.65 [‐4.94, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">High‐dose buprenorphine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002207.pub4/references#CD002207-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002207.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002207-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002207-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002207-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002207-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002207\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002207\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002207\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002207\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002207\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002207.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002207.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002207.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002207.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002207.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718772855"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002207.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718772858"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002207.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd8838edd935f',t:'MTc0MDcxODc3My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 